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ABSTRACT 
 
 
Kidney diseases are a major problem of worldwide proportion. A large number 
of herbs have been used traditionally to treat kidney diseases caused by various 
agents. The present study was a similar attempt in that direction. Helicanthes 
elastica is a less explored Indian mistletoe. Methanolic extract of Helicanthes 
elastica(MHE) was evaluated for antiurolithiatic and nephroprotective activity 
in Wistar rats. For antiurolithiatic study, male Wistar rats were selected and 
ethylene glycol (0.75%v/v) in drinking water was fed to all the groups except 
normal control for 28days to induce urolithiasis for preventive and curative 
regimen. Cystone 750mg/kg was used as the standard drug.   Various renal 
functional  and  injury  markers  such  as  urine  volume,  calcium,  magnesium, 
serum creatinine, serum uric acid and blood urea nitrogen were evaluated in 
urine  and  serum  samples.  The  result  indicated  that  administration  of MHE 
significantly reduced and prevented the growth of urinary stones. 
Histopathological studies also supported the result. In nephroprotective study, 
Wistar  rats   of  either   sex   selected  and   renal   toxicity  was   induced   by 
administering cisplatin 5mg/kg i.p on first day. From day 2 to day 14 animals of 
all groups except normal group were administered with MHE. Cisplatin induced 
renal damage is clearly evidenced by the elevated levels of serum markers like 
urea, creatinine and uric acid. The treatment with the extract regained the 
elevated levels of renal injury markers in serum to normal levels. 
Histopathological reports also supported the result. This study suggests that the 
MHE offers protection against ethylene glycol induced urolithiasis and cisplatin 
induced nephrotoxicity 
Keywords: Helicanthes elastica; Urolithiasis; Ethylene glycol; Nephrotoxicity; 
Nephroprotection; Cisplatin; Cystone; Histopathology. 
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INTRODUCTION 
 
 
Medicinal plants have been known for millennia and are being used as a rich 
source of therapeutic agents worldwide. WHO reported that nearly 75% global 
population, most in the developing world depends on the botanical medicines 
for  their  basic  health  care  needs  with  around  800  plants  being  used  in 
indigenous systems of medicines. The use of herbal medicine is becoming 
popular due to toxicity and side effects of allopathic medicines. 
 
India is one among the world‟s 12 hot spot having the largest plant biodiversity 
and it has almost 45,000 plant species, of which 15,000 to 20,000 are used for 
medicinal purposes. Indian civilization has played a pioneer role from time 
immemorial in utilizing plants such as indigenous drugs and has the unique 
distinction of having 6 recognized systems of medicine in this category. They 
are Ayurveda, Siddha, Unani, Yoga, Naturopathy and Homeopathy.A large no 
of healers in the folklore stream is another system that has not been recognized 
under  any  category.
1,2
The  major  classical  system  of  medicines  used  in 
 
Ayurveda, Siddha and Unani together use about 1200 plant species to treat 
human ailments whereas the tribes of India use more than 7500 plant species. 
Ethno medicinal practices are the mother of all other traditional systems. 
Traditional medicine is the sum total of knowledge skills and practices based on 
the theories, beliefs and experiences indigenous to different cultures. Whether 
explicable or not, used in the maintenance of health as well as in the prevention, 
diagnosis, improvement or treatment of physical and mental illnes. Traditional 
folk medicine serves as the root of Ayurveda. 
2
Historically and culturally, oral 
 
folk traditions have had a symbiotic relationship with codified Indian medical 
systems like Ayurveda, Siddha, Unani and Swarigpa. The medical research and 
commerce exploited many valuable experiences from the oral health 
traditions.WHO estimated that 80-90% of the world‟s population relies mainly 
on the local herbal practitioners. Various studies revealed that about 80% of the 
population of developing countries partially or fully depends on herbal drugs for 
primary health care. Traditional medicine relies on higher plants as the main 
source of drug therapy. Herbal medicine is not just a poor man‟s substitute for 
conventional medicine but a valuable form of treatment in its own right. The
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rising cost of the prescription drugs which are being used in the maintenance of 
normal/ personal health and wellbeing fuelled the reliability of man‟s interest in 
medicinal plants as a remerging health aid. 
 
Human  body,  for  its  normal  functioning  deals  with  hundreds  of 
thousands of independent factors which involves interactions of a large no of 
proteins and cells working with environmental factors. Even a small interruption 
in  this  interaction  can  cause  a  state  of  discomfort  in  which  the  normal 
functioning of the body is affected which is generally termed as a disease. 
Kidney, an important excretory organ in the human body function not only to 
excrete the metabolic waste products, but also to maintain the acid base balance 
and endocrine functions like erythropoietin production. Urolithiasis and 
nephrotoxicity are two common problems faced by the people in the current 
days. 
 
Urinary stone disease has been a challenge for the humankind since a long time 
and can lead to serious health consequences for patients throughout their life. 
Urolithiasis (urinary calculi or stone) , one of the most common urinary tract 
disease with worldwide prevalence and incidence refers to the calcification that 
form in the urinary system, primarily in the kidney referred to as nephrolithiasis 
or ureter as ureterolithiasis   and may also form in or migrate into the lower 
urinary system either in the bladder or urethra. The etiology behind the disorder 
is multifactorial and the lifestyle habits or practices strongly contribute to it. 
Diet  and  lifestyle  are  the  two  major  factors  thought  to  influence  the 
susceptibility to many diseases.
3 
Urolithiasis can be classified under a life style 
 
disease. Any factor that reduces the urinary flow or causes obstruction which 
results in urinary stasis or reduces urinary volume through dehydration and 
inadequate fluid intake, increase the risk of developing stones.
4
Thus urolithiasis 
is a complex process that results from several physicochemical events including 
crystal nucleation, aggregation and growth of insoluble particles in the kidney. 
 
Urinary stones have been documented historically as far as back as the Egyptian 
mummy. The archaeological findings give profound evidence that for centuries 
human have been suffering from kidney and bladder stones. 
5
The term 
urolithiasis is originated from the French word “urine” which in turn, stems
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from the Latin term “urina” and the Greek “Ouron” meaning urine .The stones 
themselves are called as renal calculi. The word “calculus”( plural calculi) is the 
Latin word for pebble. 
 
Urolithiasis  is  a  worldwide  problem.  It  is  estimated  that  12%  of  world 
population experiences renal stone disease with a recurrence rate of 70-80% in 
men and 47-60 in women and in economically developed countries the 
prevalence rate ranged between 4% and 20%.
6, 7
Women have a bio modal age of 
onset, with episodes peaking at 35 and 55 years. Without preventive treatment 
the recurrence rate of calcium oxalate calculi increases with time and reaches 
50% at 10 years. 
8
 
 
 
Nephrotoxicity is one of the most common kidney problems and occurs when 
body  is  exposed  to  a  drug  or  toxin.  A  number  of  therapeutic  agents  can 
adversely affect the kidney resulting in acute renal failure, chronic interstitial 
nephritis  and  nephritic  syndrome  because  there  is  an  increasing  number of 
potent therapeutic drugs like aminoglycoside antibiotics, NSAID‟s, 
chemotherapeutic agents have been added to the therapeutic arsenal in recent 
years. Exposure to chemical reagents like ethylene glycol, carbon tetrachloride, 
sodium oxalate and heavy metals such as lead, mercury, cadmium and arsenic 
also induces nephrotoxicity. Prompt recognition of the disease and cessation of 
responsible drugs are usually the only necessary therapy. Nephroprotective 
agents are the substances which possess protective activity against 
nephrotoxicity. Medicinal plants have curative properties due to the presence of 
various complex chemical substances. Early literatures have prescribed various 
herbs for the cure of renal disorders. Co-administration of various medicinal 
plants possessing nephroprotective activity along with different nephrotoxic 
agents  may  attenuate  its  toxicity.  The  term  renal  failure  primarily  denotes 
failure of the excretory function of kidney, leading to retention of nitrogenous 
waste products of metabolism in the blood. In addition to this, there is a failure 
of regulation of fluid and electrolyte balance along with endocrine dysfunction. 
The renal failure is  fundamentally categorized  into acute and chronic renal 
failure.
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Even though kidney stone and nephrotoxicity was categorised among one of the 
most prevalent and widespread disease in the world, till date no guaranteed cure 
is found for the same. None of the known and available treatments prevent the 
reoccurrence  of  kidney  stone  formation  and  toxicity produced  by cisplatin. 
Hence the dire need for the herbal formulation appears to be the need of the 
hour. The present study was carried out to evaluate the anti urolithiatic and 
nephroprotective activity of the methanolic extract of the whole plant 
Helicanthes elastica. 
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AIM & OBJECTIVE 
 
 
 
AIM 
 
To evaluate the Antiurolithiatic and Nephroprotective activity of the methanolic 
extract of aerial parts of Helicanthes elastica (Desr.) Danser. 
 
 
OBJECTIVES 
 
Phase 1 
 
  Literature survey 
 
Phase 2 
 
  Identification and authentication of Helicanthes elastica. 
 
  Collection, shade drying and powdering of leaves. 
 
  Preparation of the methanol (80%) extract by Soxhlet extraction. 
 
  Preliminary   phytochemical   screening   to   investigate   the   chemical 
composition. 
Phase 3 
 
  Submission of application to IAEC. 
Phase 4 
  To evaluate the Antiurolithiatic activity 
 
Ethylene glycol induced urolithiasis. 
 
  To evaluate the nephroprotective activity 
 
Cisplatin induced nephrotoxicity 
 
Phase 5 
 
  Statistical evaluation- ANOVA and scientific documentation.
  Page 10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW 
OF 
 
LITERATURE 
and 
background
  Page 11 
 
 
 
 
 
REVIEW OF LITERATURE AND BACKGROUND 
 
 
PLANT PROFILE 
 
 
Mistletoe is the common name for the most obligate hemi parasite plants in the 
order Santalales. They attach to and penetrate the branches of a tree or shrub by 
a structure called haustorium through which they absorb water and nutrients 
from the host plant. In India 6 mistletoes   are considered to have   medicinal 
properties in which two belongs to genus Loranthus and four to the genus 
Viscum. Helicanthes  elastica (Desr.)Danser belonging to the family 
Loranthaceae is a less known Indian mistletoe growing commonly on mango 
tree (Mangifera indica) as hemiparasites. 
 
 
 
 
Fig 1.Helicanthes elastica growing on mango trees 
 
 
Synonyms 
 
 
Helicanthus elastica (Desr.)Danser 
Dendrophthoe elastica(Desr.) Danser 
Loranthus elasticus Desr. 
Loranthus euphorbiae Wight
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IBP Taxonomy Hierarchy 
 
 
Kingdom: Plantae Phylum  
: Tracheophyta Class      :  
Magnoliopsida Order     :  
Santalales Family  :  
Loranthaceae Genus    :  
Helicanthes 
Species  : Helicanthes elastica 
 
 
Description 
9
 
 
 
It is a hemi parasitic dichotomously branched, glabrous; pendulous shrub with 
swollen joints, the young branches being green and flowers white in colour. 
 
Leaves: opposite 4-8 X 1.5-4cm, ovate or elliptic oblong, base: - obtuse or 
truncate, apex:-acute or obtuse, thickly coriaceous, glaucous beneath, basically 
three nerved sessile or sub sessile. 
 
Flowers:  aggregated in short axillary fascicles. 
 
 
Flower colour: green, white 
 
 
Calyx:  minute, flask shaped, margin truncate. 
 
 
Corolla: white with green stripes, 2.5- 3.5cm long, split lengthwise into 5 linear, 
twisted lobes. 
 
Stamen: five exserted, filament crimson. 
 
 
Ovary: 1.5mm long 
Style: 3-3.5cm long 
Stigma: ovoid 
Berry: 6-8 x 3- 3.5mm, obovoid red.
Literature review of plant Helicanthes elastica 
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Stem parasite: yes 
 
 
Flowering and fruiting: December –March 
 
 
Habitat: Evergreen and moist deciduous forest, also in the plains 
 
 
Distribution: mainly in Western Ghats 
 
 
Altitude: 600-750 
 
 
Uses 
 
 
Traditional use: The leaves of Helicanthes elastica were  used to check abortion 
 
. It is also used in vesical calculi and kidney infections. Leaves are used as 
poultices in sores and ulcers. 
 
Pharmacologically reported activities:- 
Antimicrobial activity 
10
 
Antioxidant activity 
11
 
 
 
Antihyperglycemic activity 
12
 
 
 
Hepatoprotective activity 
13
 
 
 
Diuretic and natriuretic activity 
14
 
 
 
Chemical Constituents 
 
 
The whole plant of Helicanthes elastica is found to contain sterols, terpenoids, 
flavones, tannins and glycosides. Alkaloids, Quinone‟s and Coumarins were 
absent. 
 
The presence of compounds viz,1-octadecene,neophytadeine,hexadecanoic acid 
ethyl ester, octadecanoic acid ethyl ester, stigmasterol, γ-stigmasterol, β- 
stigmasterol-3-ol,  pentacosane  and    -sitost-4-en-3-one  by  GC-MS  analysis 
were also reported. The column chromatography of the ethyl acetate extract also 
showed the presence of friedelin, epifriedelinol, β amyrin, β sitosterol, ethyl 
Literature review of plant Helicanthes elastica 
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gallate, gallic acid and β sitosterol 3-β-D glucopyranoside.15, 16, 17 
 
Sunil  et  al.,  (2015)  evaluated  the  phytoconstituents  of  Helicanthus  elastica 
whole plant. The presence of compounds viz,1-octadecene, neophytadeine, 
hexadecanoic acid ethyl ester, octadecanoic acid ethyl ester, stigmasterol, γ- 
stigmasterol, β-stigmasterol-3-ol, pentacosane and   -sitost-4-en-3-one   were 
detected by GC-MS analysis and 7 compounds viz, friedelin, epifriedelinol, β 
amyrin,   β   sitosterol,   ethyl   gallate,   gallic   acid   and   β   sitosterol   3-β-D 
glucopyranoside by column chromatography were reported.
15
 
 
 
Sunil  et al., (2014) reported the antimicrobial potential of Helicanthus elastica 
(Desr.) Danser (Loranthaceae). The  zone of inhibition and minimum inhibitory 
concentration were assayed   by standard methodologies against bacteria like 
Aeromonas hydrophila, Bacillus subtilis, Escherichia coli, Klebsiella 
pneumoniae, methicillin-resistant Staphylococcus aureus, Pseudomonas 
aeruginosa, Streptococcus pyogenes, Vibrio fischeri, and a fungus Candida 
albicans. The study concluded that, of the eight tested bacteria, the alcoholic 
extract of H. elastica was found to be active against K. pneumoniae, A. 
hydrophila,  E.  coli,  and  V.  fischeri  at  concentration  ranging  from  250  to 
500μg/ml  and  C.  albicans  showed  inhibition  only  at  a  concentration  of 
 
2000μg/ml.10 
 
 
 
Sunil  et  al.,  (2016)  reported  the  hepatoprotective  activity  of  Helicanthus 
elastica.  The  acute  oral  toxicity study conducted  on  the  aqueous  and  95% 
ethanolic extract of whole plant of Helicanthus elastica revealed that the extract 
is safe up to a dose of 2000 mg/kg body. The hepato protective activity of the 
extract(200 and 400mg/kg body weight) against paracetamol induced toxicity 
was  evidenced  by  significant  reduction  in  the  elevated  serum  transaminase 
levels and the histopathological studies that showed marked reduction in the 
fatty degeneration and centrizonal necrosis, in animals receiving different doses 
of extract along with paracetamol as compared to the control group. 
13
 
 
 
Sunil  et  al.,  (2013)  developed  the  finger  print  profile  of  chloroform  and 
ethanolic extracts of Helicanthus elastica. The presence of different marker
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compounds was reported by fingerprinting the extract in suitable solvent system 
and  by scanning  densitometrically under  UV  and  after  dipping  in  vanillin- 
sulphuric acid reagent followed by heating at 105°C. The study revealed 
differentiating  fingerprints  which  are  helpful  in  the  authentication  of  H. 
elastica.
16
 
 
 
Sunil et al., (2014) reported the total phenol content and antioxidant properties 
of the ethanolic extract of Helicanthus elastica using different in vitro models. 
The total phenol content, reducing power assay and scavenging of free radicals 
like nitric oxide, hydroxyl, hydrogen peroxide, and 1,1-diphenyl-2- 
picrylhydrazyl were evaluated  by standardized in vitro chemical methods using 
ascorbic acid as the standard and reported that  the total phenol content of the 
plant  to be 1.89% w/w. The study also reported that the extract showed good 
reducing power as well as scavenging of free radicals (nitric oxide, hydroxyl, 
superoxide anion, and hydrogen peroxide) at concentrations ranging from 5 to 
100μg/ml. 11 
 
 
Sunil et al., (2015) reported the molecular differences in the genomic DNA of 
the plant while growing on five different host trees using four random markers 
employing random amplified polymorphic DNA (RAPD) followed by similarity 
matrix by Jaccard‟s coefficient and distance matrix by hierarchal clustering 
analysis. The study reported that the DNA of H. elastica differs depending upon 
the host on which it grows, hence the host must be considered while studying or 
utilizing this mistletoe for medicinal purposes.
17
 
 
 
Sunil et al., (2014) studied the whole plant of Helicanathus elastica for 
physicochemical and nutraceutical analysis aiding standard methodology. They 
fingerprinted the total ethanolic extract with HPLC-UV. Under the head 
physicochemical examination, determined various parameters like moisture 
content, total ash, water-soluble ash, acid-insoluble ash, alcohol-soluble and 
water-soluble   extractive,   successive   extractive   values   by   cold   and   hot 
extraction, heavy metals like arsenic, lead, cadmium and mercury, total bacterial 
count, total fungal count, presence of enterobacteriaceae, Escherichia coli, 
Salmonella  spp.,  Pseudomonas  aeruginosa  and  Staphylococcus  aureus    and
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presence of carbohydrate, fat, protein and fibre, calorific value, vitamins like 
niacinamide, pyridoxine, riboflavin, thiamine and ascorbic acid, trace elements 
like iron and zinc. The investigations revealed the presence of appreciable 
quantity of important vitamins and trace elements in the plant.
18
 
 
Rajesh et al., (2015) evaluated the anti-hyperglycaemic activity of methanolic 
extract of Helicanthus elasticus on Streptozotocin induced diabetic rats. The 
activity  was  confirmed  by observing  the  significant  reduction  in  the  blood 
glucose level at 0, 30, 60,120 and 240 min in fasted and glucose loaded diabetic 
rats in acute studies and at 1
st
, 7
th
, 14
th  
and 21
st  
day in sub-acute studies of 
Streptozotocin induced diabetic rats after extract administration at 200 mg/kg 
body weight. Thus they concluded that in both acute and sub-acute studies, the 
methanolic extract  has  shown  statistically significant  antihyperglycemic  and 
glucose tolerance activity.
12
 
 
Shihab  et  al.,  (2006)  studied  the  antioxidant,  antinociceptive,  and  general 
toxicity of the ethanolic extract of the leaves of H.elastica. The extract showed 
potent antioxidant activity (IC50 5.1 μg/ml) using DPPH radical scavenging 
assay, which is comparable to the standard ascorbic acid (IC50 4.6 μg/ml). They 
also reported that the extract significantly and dose dependently inhibited the 
acetic acid induced writhing in mice (71.2%, P < 0.001 and 28.0%, P < 0.05 for 
500 and 250 mg/kg body weight, respectively). Using different chromatographic 
techniques, quercitrin (quercetin 3-O-α-rhamnoside) was separated as the major 
component from the extract and elucidated the structure by detailed 1D and 2D 
NMR and mass spectral analysis.
19
 
 
Namita et al., (2010) reported the diuretic activity of methanolic extracts of 
Viscum articulatum (VA) Burm. f. and Helicanthus elastica (HE) (Ders.) Dans. 
in rats. Diuretic, saluretic and natriuretic effects were reported after the oral 
administration of the extracts. The polyphenolic and triterpenoid contents were 
determined quantitatively using chemical assays and high performance liquid 
chromatography (HPLC) analysis respectively. Phytochemical analysis revealed 
the presence of polyphenolics and  triterpenoids, such as oleanolic acid and 
lupeol,   as   the   major   phytochemicals   involved.   A   higher   content   of
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polyphenolics  in  association  with  lower  triterpenoid  content  was  found  to 
favour potassium-sparing effects.
14
 
 
 
KedarKalyani et al., (2012) Studied the triterpenoid pattern of cuticular wax of 
leaves of Helicanthus elasticus Linn. (Loranthaceae) parasitic on Memecylonum 
bellatum Burm.f. (Melastomataceae)  and compared with standard triterpenoids 
such  as  lupeol,  olenolic  acid  and  betulin.  The  cuticular  extract  was  also 
subjected to column chromatography and characterised the isolated compounds 
by UV, IR, HPTLC and MS studies and compared with standards. From the 
results they concluded that the cuticular wax  of  Helicanthus elasticus Linn 
shows presence of lupeol.
20
 
 
 
 
Nipun  et  al.,  (2011)  explored  the  anticancer  activity  of  the  ethanolic  and 
aqueous extracts of the  Dendrophthoe falcate  in Swiss albino mice against 
Ehrlich Ascites Carcinoma (EAC) cell line. The significant decrease (p<0.0001) 
in the tumor volume, viable cell count, tumor weight and elevated  life span of 
EAC tumor bearing mice after the administration of ethanolic extract  (200 and 
400 mg/kg body) for 13 consecutive days were considered as the parameter to 
confirm the anticancer ativity . Haematological profiles such as red blood cell 
(RBC), haemoglobin, and white blood cell (WBC) count reverted to normal 
level in treated mice. The results demonstrated that the extract has potent dose 
dependent anticancer activity comparable to that of cisplatin. 
21
 
 
 
Pattanayak et al., (2008) Investigated the ethanolic extract of aerial parts of 
Dendrophthoe falcata for the evaluation of its healing efficiency on excision 
and  incision  wound  models  in  rats.  The  results  showed  that 
Dendrophthoefalcata extract has potent wound healing capacity as evident from 
the wound contraction and increased tensile strength. Correlation of 
Hydroxyproline and hexosamine expressions with the healing pattern was also 
reported. The  antimicrobial activity of various fractions of extract (petroleum 
ether, chloroform and ethanol) were   also reported by screening against the 
organisms: Staphylococcus aureus, Staphylococcus pyogenes, Staphylococcus 
epidermidis, Micrococcus luteus, Bacillus subtilis, Bacillus cereus, Klebsiella 
pneumoniae,   Enterobacter   aerogenes,   Pseudomonas   aeroginosa,   Serratia
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marcescens, and five fungi Candida albicans, Candida tropicalis: dimorphic 
fungi, Aspergillus fumigatus, Aspergillus niger: systemic fungi, and some 
infectious bacteria Escherichia coli, and Salmonella typhi and has reported a 
positive result.
22
 
 
Osadebe et al., (2014) reported   the hypoglycaemic and anti-hyperglycemic 
activities of dried leaves of Loranthusmicranthus (Linn.) (Loranthaceae), 
parasitic on Persea americana, Baphianitda, Kola acuminata, Pentaclethra 
macrophylla,   Azadirchta   indica,   in   normoglycemic   and   alloxan-induced 
diabetic  albino  rats.  Intraperitoneal  administration  with  200 mg/kg  of  the 
respective methanolic extracts of Loranthus micranthus (Linn.), glibenclamide 
(positive control), and 20% (v/v) Tween 20 solution (negative control) showed 
significant reduction in the sugar levels of the withdrawn blood samples in 
Normoglycemic and alloxan-induced diabetic rats .
23
 
 
 
 
 
KIDNEY 
 
The paired kidneys are reddish, kidney-bean-shaped organs located just above 
the waist between the peritoneum and the posterior wall of the abdomen. The 
kidneys are located between the levels of the last thoracic and third lumbar 
vertebrae. The liver occupies considerable space on the right side superior to the 
kidney. 
 
 
Anatomy of the kidneys 
 
An adult kidney is 10-12cm long, 5-7 cm wide and 3 cm thick. The concave 
medial border of each kidney faces the vertebral column. Three layer of tissue 
surround each kidney. The deep layer, the renal capsule is a smooth, transparent 
sheet of dense irregular connective tissue. The middle layer, the adipose capsule 
is a mass of fatty tissue surrounding the renal capsule. The superficial layer, the 
renal fascia is another layer of dense irregular connective tissue. 
The frontal section through the kidney reveals two distinct regions. The 
superficial region is called renal cortex, a smooth-textured reddish area. The 
deep reddish-brown inner region is called the renal medulla. It consists of 8-18 
cone-shaped renal pyramids. 
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Together, the renal cortex and renal pyramids of the renal medulla constitute the 
parenchyma   of   the   kidney.   Within   the   parenchyma   about   one   million 
microscopic structures are present called nephrons. Nephrons are the functional 
units of the kidney. Each nephron consists of two parts, a renal corpuscle, where 
blood plasma is filtered and renal tubule into which the filtered fluid passes. 
Blood supply to the kidneys is provided by renal artery that rises from the aorta. 
Venous tributaries unite to form the single wide renal veins which drain into the 
inferior vena cava. Nerve supply is provided by sympathetic nerves originated 
in the 12th thoracic and 1st lumbar segments. The parasympathetic nerves are 
derived from the vagi. The frontal section of the right kidney is shown in figure 
2. 
 
 
 
 
 
Figure 2: Frontal section of the right kidney 
 
 
Nephrons 
 
 
Nephrons are the structural and functional units of the kidney. Each nephron 
consists of a glomerulus, proximal tubule-comprising convoluted and straight 
segments,  loop  of  Henle,  distal  convoluted  tubule and  collecting duct.  The 
glomerulus comprises a tuft of capillaries projecting into a dilated end of the
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renal tubule. Most nephrons lie largely or entirely in the cortex. The remaining 
 
12%, called the juxtamedullary nephrons, have their glomeruli and convoluted 
tubules next to the junction of the medulla and cortex, and their loops of Henle 
pass deep into the medulla. In juxtamedullary nephrons, part of the thick 
ascending limb of the loop of Henle (as well as the thin part of the loop) lies in 
the medulla; the part of the medulla containing the thick ascending limb is 
known as the outer stripe of the medulla, as opposed to the inner stripe, which 
contains thin segments only. 
 
 
 
Histology of the kidney 
 
Each kidney consists of a medulla and a cortex which is both outside and 
between the pyramids. In the latter situation the cortex forms the renal columns 
through which pass the renal vessels. The histological and functional unit of the 
kidney  is  nephron  (renal  tubule)  composed  of  a  glomerular  (Bowman‟s) 
capsule, a proximal convoluted tubule, a loop of Henle, a distal convoluted 
tubule and a collecting duct. 
The cup-like glomerular capsule lies in the cortex around a tuft of capillaries, 
the glomerulus, and leads into the proximal convoluted tubule. The loop of 
Henle descends into the medulla nearly as far as the apex of the pyramid and 
then returns to the cortex and continues as the distal convoluted tubule. The 
distal tubules join the collecting ducts which pass through the medulla and open 
on the surface of a renal papilla into a minor calyx. The glomerular capsule is 
lined by thin specialized epithelium, cubical epithelium lines. The proximal and 
distal convoluted tubules are adjacent parts of the loop of Henle. The rest of the 
loop is lined by simple squamous and the collecting ducts by columnar 
epithelium. 
 
Functions of the kidneys 
 
a) Formation of urine. 
 
The production of urine is vital to the health of the body. Most of us have 
probably never thought of urine as valuable, but we could not survive if we did 
not produce it and eliminate it. The composition of urine reflects the activities 
of the nephrons in the maintenance of homeostasis. Waste products of protein 
metabolism are excreted, electrolyte balance is maintained and the acid-base
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balance is influenced by the excretion of hydrogen ions. To produce urine, 
nephrons and collecting ducts perform three basic processes. 
• Glomerular filtration 
 
• Tubular reabsorption 
 
• Tubular secretion 
 
 
 
 
 
 
 
 
Figure3 : Urine formation 
 
 
 
b) Regulation of blood ionic composition. 
 
The kidneys help regulate the blood levels of several ions, most importantly 
sodium ions (Na
+
), potassium ions (K
+
), calcium ions (Ca
++
), chloride ions (Cl¯) 
and phosphate ions (HPO4
2¯
). 
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c) Regulation of blood pH. 
The kidneys excrete a variable amount of hydrogen ions (H
+
) into the urine and 
conserve bicarbonate ions (HCO3¯), which are an important buffer of H
+ 
in the 
blood. Both of these activities help to regulate blood pH. 
d)Regulation of blood volume. 
 
The kidneys adjust blood volume by conserving or eliminating water in the 
urine. 
e) Regulation of blood pressure. 
 
The kidneys help to regulate blood pressure by secreting the enzyme renin, 
which activates the renin-angiotensin-aldosterone pathway. Increased renin 
causes an increase in blood pressure. 
f) Maintenance of blood osmolarity. 
 
By separately regulating loss  of  water and  loss  of solutes  in  the urine the 
kidneys maintain relatively constant blood osmolarity close to 300 milliosmoles 
per liter. 
g) Production of hormones. 
 
The kidneys produce two hormones. Calcitriol, the active form of vitamin D, 
helps to regulate calcium homeostasis and erythropoietin stimulates production 
of red blood cells. 
h) Regulation of blood glucose level. 
 
The kidneys can use amino acid glutamine in gluconeogenesis, the synthesis of 
glucose molecule. Then they release glucose into blood to maintain normal 
glucose level. 
i)Excretion of wastes and foreign substances 
 
By forming urine, kidneys help to excrete wastes ( substances that have no 
useful function in the body) 
 
UROLITHIASIS 
 
 
The formation of stone in the urinary system, i.e. in the kidney, ureter, and 
urinary bladder or in the urethra is called urolithiasis. „Urolithiasis‟ = ouron 
(urine) and lithos (stone). Urolithiasis is one of the major diseases of the urinary 
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tract and is a major source of morbidity. Stone formation is one of the painful 
urologic disorders that occur in approximately 12% of the global population and 
its re-occurrence rate in males is 70-81% and 47-60% in female. It is assessed 
that at least 10% of the population in industrialized part of the world are 
suffering with the problem of urinary stone. It has been found that the formation 
of urinary calculi dates back not only to 4000 B.C in the tombs of Egyptian 
mummies also in graves of North American Indians from 1500 to1000 B.C. 
Stone formation is also documented in the early Sanskrit documents during 
3000 and 2000 B.C. The problem of stone formation is considered as a medical 
challenge due to its multifactorial etiology and high rate of reoccurrence. Stone 
formation is also caused due to imbalance between promoters and inhibitors. 
 
CLASSIFICATION OF STONES 
 
 
The crystalline mineral deposits that form in the kidney constitute the renal 
calculi. They develop as microscopic crystals in the Loop of Henle, the distal 
tubule, or the collecting duct  and they can enlarge to form visible fragments.A 
large number of factors contribute to the formation of calculi and are formed by 
different mechanisms. The process of stone formation depends on urinary 
volume, concentration of calcium, phosphate, oxalate, sodium and uric acid 
ions;  concentration  of  natural  calcium  inhibitors  like  citrate,  magnesium, 
bikunin, etc. and the urinary pH
26
High ion levels, low urinary volume, low pH. 
 
and low citrate levels also favours calculi formation. 
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The most common type of stones occurring were as follows 
Table 1: Common types of stones 
 
 
Name of stone Constituents Incidence 
Calcium oxalate Calcium, oxalate 34% 
Calcium phosphate Calcium, phosphate 33% 
Uric acid Uric acid 8% 
Struvite Ammonium,magnesium,phosphate 15% 
Cystine Cystine 3% 
Medication      induced 
 
stones 
Depends  on  the  medication  (eg; 
 
Indinavir,   ephedrine,   
Guaifensin, silica etc) 
1% 
 
 
 
 
 
 
 
 
Figure 4: Different types of Stones
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Calcium oxalate stones 
 
  Most common type and represent about 80% 
 
  Contains  calcium  oxalate  alone  or  in  combination  with  calcium 
phosphate in the form of apatite or brushite 
  They  appear  as  'envelopes'  microscopically.  They  may  also  form 
 
'dumbbells‟ 
 
  Hydrated  forms  of  the  compound  occur  naturally  as  three  mineral 
species: whewellite (monohydrate, known from some coal beds), 
weddellite (dihydrate) and a very rare trihydrate called caoxite. 
27
 
 
  Formation of calcium phosphate stones is associated with conditions 
such as hyperparathyroidism and renal tubular acidosis. 
  Oxaluria is increased in patients with certain gastrointestinal disorders 
including inflammatory bowel disease such as Crohn disease or patients 
who have undergone resection of the small bowel or small bowel bypass 
procedures and in patients who consume increased amounts of oxalate 
(found  in  vegetables  and  nuts).  Primary  hyperoxaluria  is  a  rare 
autosomal recessive condition which usually present in childhood. 
28
 
 
 
Struvite stones (Ammonium magnesium phosphate, NH4MgPO4•6H2O) 
 
  Constitute about 10-15% of urinary calculi. 
 
  Also known as infection stones 
 
  Magnesium, ammonium and phosphorus are the building blocks for the 
formation of Struvite crystals in urine 
  They have „coffin lid' morphology by microscopy. 
 
  They form  most  often  in  the presence  of infection  by urea-splitting 
bacteria. 
  Using  the  enzyme  urease,  these  organisms  metabolize  urea  into 
ammonia and carbon dioxide which alkalinizes the urine, resulting in 
favourable conditions for the formation of struvite stones. 
  In addition, urine pH and its influence on the concentration of trivalent 
 
ionic phosphate (PO4
3-
) play a key role in struvite crystallization. As 
1-                         2-urine pH increases, H3PO4, H2PO4 and HPO4 are rapidly deprotonated
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(i.e., removal of hydrogen ions) increasing the concentration of PO4
3- 
a 
principal component and driving force for struvite crystal formation. 
  Commonly observed in people who have factors that predispose them to 
urinary tract infections, such as those with spinal cord injury and other 
forms of neurogenic bladder, ileal conduit urinary diversion, vesico 
ureteral reflux, and obstructive uropathies and in people with underlying 
metabolic disorders, such as idiopathic hypercalciuria, 
hyperparathyroidism, and gout. Infection stones can grow rapidly, 
forming large calycealstaghorn (antler-shaped) calculi requiring invasive 
surgery such as percutaneous nephrolithotomy for definitive treatment.
29
 
 
 
 
Uric acid stones 
 
  About 5–10% of all stones are formed from uric acid. 
 
  They appear  as  pleomorphic  crystals,  usually diamond-shaped.  They 
may also look like squares or rods which are polarizable. 
28
 
  People with certain metabolic abnormalities; including obesity    may 
produce uric acid stones. They also may form in association with 
conditions that cause hyperuricosuria (an excessive amount of uric acid 
in the urine) with or without hyperuricemia (an excessive amount of uric 
acid in the serum) and   in association with disorders of acid/base 
metabolism where the urine is excessively acidic (low pH), resulting in 
precipitation of uric acid crystals. 
30
 
 
Cystine stones 
 
  Constitutes about 3% of the urinary calculi. 
 
  Mainly caused due to cystinuria, an inherited (genetic) disorder of the 
transport of an amino acid (a building block of protein) called cystine 
that results in an excess of cystine in the urine (cystinuria) and the 
formation of cystine stones. 
  Although  cystine  is  not  the  only  overly  excreted  amino  acid  in 
cystinuria, it is the least soluble of all naturally occurring amino acids. 
  Cystine tends to precipitate out of urine and form stones (calculi) in the 
urinary tract.
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  Small stones are passed in the urine. However, big stones remain in the 
kidney (nephrolithiasis) impairing the outflow of urine while medium- 
size stones make their way from the kidney into the ureter and lodge 
there further blocking the flow of urine (urinary obstruction). 
  Obstruction of the urinary tract puts pressure back up on the ureter and 
kidney causing the ureter to widen (dilate) and the kidney to be 
compressed. Obstruction also causes the urine to be stagnant (not 
moving), an open invitation to repeated urinary tract infection. The 
pressure on the kidneys and the urinary infections results in damage to 
the kidneys. The damage can progress to renal insufficiency and end- 
stage kidney disease, requiring renal dialysis or a transplant
. 31
 
 
 
 
Silicate stones or drug induced stones 
 
  Very rarely observed 
 
  Formed as a result of taking certain medications or herbal products and 
the subsequent build-up of chemicals from those products in the urine. 
Some of these are Loop diuretics, Acetazolamide, Topiramate, 
Zonisamide, Laxatives (when abused), Ciprofloxacin, 
Sulfamedications,Triamterene, Indinavir, Ephedrine, Guaifenesin, and 
products containing silica. 
 
 
ETIOLOGY OF STONE FORMATION 
 
 
Stone  formation  is  usually  multi-factorial  with  more  than  one  element 
increasing a patient„s risk for stone formation and is strongly related to dietary 
lifestyle habits or practices. Increased rates of hypertension and obesity, which 
are   linked   to   nephrolithiasis,   also   contribute   to   an   increase   in   stone 
formation.
32
About  25% of patients  with  urolithiasis  may be the result  of a 
 
polygenic  defect  with  partial  penetrance.  Several  disorders  that  cause  renal 
stones are hereditary and they are renal tubular Acidosis and 
Cystinuria.
33
Xanthinuria and dihydroxyadeniuria are rare hereditary disorders. 
A slightly higher rate of renal stone disease is reported in males than in females. 
Men are affected approximately 4 times more often than women. The rate of 
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occurrence is three times higher in men than women, because of enhancing  
capacity of testosterone and inhibiting capacity of oestrogen in stone formation. 
The prevalence of urinary calculi is higher in mountainous, desert or tropical 
areas. Other high incidence areas are the British Isles, Scandinavian countries, 
Mediterranean countries, Northern India and Pakistan, Northern Australia, 
Central Europe, portions of the Malayan Peninsula and China 
Increased water intake and increased urinary output decrease the incidence of 
urinary  calculi  in  those  patients  who  are  predisposed  to  the  disease.  The 
presence or absence of certain trace elements in water has been implicated in 
the formation of urinary calculi. For example, zinc is an inhibitor of calcium 
crystallization. Dietary intake of various foods and fluids that result in greater 
urinary excretion of substances that produce stones has a significant effect on 
incidence  of  urinary  calculi.  Ingestion  of  excessive  amounts  of  purines 
oxalates,  calcium,  phosphate,  sodium  and  other  elements  often  results  
in 
excessive  excretion  of  these  components  in  urine.
34
There  is  a  relationship 
 
between occupation, social class and risk of stone formation. The risk of 
formation  of  urinary  calculi  was  increased  in  the  most  affluent  countries, 
regions, societies and individuals. These inhabitants have more disposable 
income to spend on animal protein, which leads to increased urinary 
concentrations of calcium, oxalate and uric acid.
35
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Table no 2: Major causes of calcium stone formation 
 
 
 
Condition 
 
 
Definition 
 
 
Cause 
Hypercalciuria Urinary          calcium 
 
excretion >200 mg/dl 
Absorptive hypercalciuria: 
 
↑GI     calcium     absorption 
renal. 
hypercalciuria:      impaired 
renal Calcium absorption 
Resorptivehypercalciuria: 
Primary 
hyperparathyroidism. 
Hyperoxaluria Urinary           oxalate 
 
excretion > 40mg/dl 
Primary      hyperoxaluria: 
 
genetic                      Oxalate 
  overproduction dietary 
 
Hyperoxaluria:    excessive 
dietary intake 
Enteric hyperoxaluria: ↑GI 
 
oxalate absorption 
Hypocitraturia Urinary            citrate 
 
excretion      <      320 
mg/dl 
Distal       renal       tubular 
 
acidosis:    impaired    renal 
tubular     acid     Excretion. 
Chronic                 diarrhea 
syndrome:  GI  alkali   loss 
Thiazide-induced: 
hypokalemia 
Idiopathic hypocitraturia: 
High animal protein diet, 
excessive physical exercise, 
high sodium intake. 
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Hyperu                                                                                 
ricosuria 
Urinary acid
 
excretion      >      600 
mg/dl 
Dietary  urine  excess,  uric 
 
acid overproduction or over 
excretion 
Hypomagnesuria Urinary    magnesium 
 
excretion < 50mg/dl 
Limited          intake          of 
 
magnesium-rich foods 
Gouty diathesis urinary pH < 5.5 Etiology unknown 
 
 
PATHOPHYSIOLOGY OF UROLITHIASIS 
 
 
 
A number of crystalloids of different types (oxalate, uric acid, calcium, cystine 
etc) are present in the urine which is kept in the solution by means of colloids 
like mucin and sulphuric acid by the process of absorption. 
 
When an  imbalance arises in  the  crystalloid-colloid ratio, i.e.,  an increase in 
crystalloid    and    fall    in    colloid    level  occurs,  the  crystalloids  begins  
to precipitate and adhere to the cells on the surface of renal papilla, a seed 
crystal can grow and aggregate into an organized mass. Depending on the 
chemical composition of the crystal, the stone-forming process may precede 
more rapidly when the urine pH is unusually high or low. 
27
Thus, the renal 
stones or when the colloid loses the solvent action or adhesive property, urinary 
stones are formed. 
 
Urolithiasis/Nephrolithiasis   results   in   increased   oxalate   (hyperoxaluria), 
calcium, phosphate, uric acid and cysteine in the urine. Hyperoxaluria being a 
major risk in urolithiasis leads to the activation of renin angiotensin which in 
turn increases the angiotensin II levels. Angiotensin II causes the activation of 
NADPH oxidase and as a result reactive oxygen species are generated which 
causes lipid peroxidation in the renal cell membrane. The inflammation resulted 
from the lipid peroxidation provides sites for the crystal attachment and the 
crystal so formed induces renal colic pain and chances for infections.
36
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Figure 5: Pathophysiology of  renal stone formation 
 
 
SYMPTOMS OF KIDNEY STONE 
37
 
 
 
Kidney stones can cause intense pain and blockage as they pass downwards. 
Any or some of the following symptoms are noticed:
Page 32 
 
 
 
  Severe loin pain that comes and goes in the back or side between the 
pelvis and lower rib. This is known as renal colic. The pain can move 
down into the groin or genitals 
   Nausea and vomiting 
 
   Difficulty in passing urine 
 
   Visible or microscopic traces of blood in the urine 
 
   Sweating, fever and shivers. 
 
Food and beverages that enhance the risk of calculi formation 
38
 
 
  Foods rich in organic acids (oxalates) like spinach, rhubarb, nuts and 
wheatbran. 
   Cranberry juice, apple juice, Grape fruit juice and dark colas. 
 
   Animal protein rich foods like meat, eggs and fish. 
 
   Supplements like vitamin C & D. 
 
   High intake of salt. 
 
   Alcohol. 
 
Foods and beverages that control the risk of calculi formation 
 
  Foods such as radish, beet root and horsegram. 
 
  Citrus and lemon juices, coffee, tea and soft drinks rich in citrates. 
 
  Low protein diets and fibre rich foods. 
 
  Supplements like Vitamin E, B6, and magnesium. 
 
   Low salt diets. 
 
   Beer and wine to a little extent as they contain purines. 
 
 
TREATMENT OF KIDNEY STONES 
 
 
Management of any stone is dictated by stone location, composition, size and 
patient factors e.g. co-morbidities, solitary kidney and occupation. All 
management of stones can be thought of as acute, definitive and preventative. 
Preventative management involves education of patients to decrease their risk of 
stone disease by modifying diet and hydration. Hydration is the most vital step 
in  prevention  as  chronic  dehydration  has  been  identified  as  a  cause  of 
urolithiasis. Increasing fluid intake has been shown to decrease stone incidence. 
in calcium oxalate calculus formers that increasing the urine output to greater 
than 2 litres a day, results in a 12% recurrence in stone formation, compared to
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those with no specific fluid recommendations who had a 27% recurrence of 
calculi . The goals of treatment are to control symptoms, render the patient stone 
free and prevent recurrence. 
 
Many  allopathic  agents  like  Thiazide  diuretics  (e.g.  Hydrochlorothiazide), 
Alkali (e.g. Potassium citrate), Allopurinol, Sodium cellulose phosphate (SCP), 
Penicillamine (Cuprimine), Analgesic (Diclophenac sodium), Bisphosphonates, 
Potassium phosphate, OxalobacterFormigenes and other probiotics are used in 
treating the stones formed. The ayurvedic medicines used in the treatment are 
Cystone, Calcuri, Chandraprabhabati, Trinapanchamool, Rencare Capsule, 
Patherina tablet, Ber Patthar Bhasma, Chander Prabhavati. 
 
Surgical Method
39
 
Currently there are four methods for stone removal 
a)  Extracorporeal shockwave lithotropsy. 
b)  Percutaneous Nephrolithotomy(PCNL) 
 
c)  Ureteroscopic stone removal 
d)  Open (incisional) Surgery 
 
In the present study we are adopting ethylene glycol induced urolithiasis model. 
 
 
ETHYLENE GLYCOL INDUCED UROLITHIASIS 
 
 
Ethylene glycol (EG) is a colourless, odourless, viscous dihydroxy alcohol, the 
exposure of which is toxic to the human body. Ingestion and dermal exposure 
are the two major routes of exposure to ethylene glycol in which the dermal 
exposure is unlikely to lead to toxic effects. The ingestion of EG leads to toxic 
effects. Once EG is ingested it is readily absorbed by the gastrointestinal tract. 
Distribution is rapid and occurs throughout the body. Peak concentration 
following  ingestion  occurs  within  1-4  hours.  In  humans  and  primates  the 
toxicity of EG is caused by the metabolite rather than the parent molecule. The 
liver and the kidneys are the major sites of metabolism of EG. Glycolic acid is 
the primary metabolite.
40
 
 
EG is first oxidised by alcohol dehydrogenase to glycoaldehyde, which is then 
further metabolised to glycolic acid by mitochondrial aldehyde dehydrogenase
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and cytosolic aldehyde oxidase. Glycolic acid is then metabolised to glyoxylic 
acid by glycolic acid oxidase or lactate dehydrogenase. Glycolic acid oxidase 
also catalyses the formation of oxalic acid from glyoxylicacid.Glyoxylic acid 
may be metabolised to malate, formate or glycine. Lactic acid is also formed in 
the metabolic processes following ethylene glycol exposure. It is the 
accumulation of these acid products that accounts for much of the toxicity of 
ethylene glycol. Chelation of aqueous oxalic acid with calcium ions forms 
insoluble calcium oxalate, which cannot be further metabolised by humans. 
Excretion of ethylene glycol is primarily in the urine either as the parent 
molecule,   glycolic  acid,   calcium   oxalate  or   glycine   (and   its   conjugate 
hippurate). Oxalic acid is excreted in the urine and may give rise to dihydrate 
and  or  monohydrate  oxalate  crystals  which  may  precipitate  in  the  kidney 
causing nephrotoxicity. Approximately 20% of a dose of ethylene glycol may 
be excreted unchanged by the kidneys.
41, 42
 
 
 
 
 
 
 
 
Figure 6: Metabolism of ethylene glycol
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CYSTONE
43, 44
 
 
 
Cystone is a polyherbal preparation mainly used for kidney stones, which is 
manufactured by Himalaya Herbal healthcare.Cystone also provides support in 
chronic urinary tract infection and prevents recurrence of stone formation in the 
kidneys.It also prevents lipid peroxidation and protects the kidney from various 
nephrotoxic agents. The ingredients are 
 
Shilapushpa    _    Didymocarpus pedicellata 
Pasanabheda    –    Bergenia ligulata 
Manjishtha     –     Rubia cordifolia 
Nagarmotha     –    Cyperus scariosus 
Apamarga        –    Achyranthes aspera 
Gojiha             –    Onosma bracteatum 
Sahadevi         –     Vernonia cinerea 
Main Action 
Lithontriptic or lithotropic – dissolves stones in the kidneys 
 
 
Diuretic 
 
 
Anti lithiatic – prevents and inhibits stone formation in the kidneys 
 
Reported Activity on Antiurolithiatic Property Of Herbs. 
 
Lulat et al., (2016) investigated the protective effect of Lithocare (LC) (a 
polyherbal formulation) against ethylene glycol (EG) induced urolithiasis in 
Wistar rats. Administration of EG in drinking water resulted in hyperoxaluria, 
hypocalcaemia as well as an increased renal excretion of phosphate. 
Supplementation with LC significantly reduced the urinary calcium, oxalate, 
and phosphate excretion dose-dependently. There was a significant reduction in 
the levels of calcium, oxalate as well as a number of calcium oxalate crystals 
deposits in the kidney tissue of rats administered with LC in EG-treated rats. 
There was a significant reduction in creatinine, urea, uric acid, and blood urea 
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nitrogen when LC was administered in EG-treated rats. From this study, it was 
concluded that the supplementation of LC protected EG-induced urolithiasis as 
it reduced the growth of urinary stones. 
45
 
 
Anil et al.,(2015) investigated the antiurolithiatic effect of standardized 
methanolic extract  of  Biophytum  sensitivum  (MBS) against  calcium  oxalate 
urolithiasis in rats. Calcium oxalate urolithiasis was induced in rats by ethylene 
glycol–ammonium chloride feeding in drinking water. Antiurolithiatic activity 
of MBS was evaluated in curative and preventive regimen by estimating 
histological changes in kidney and biochemical changes in urine, serum and 
kidney homogenate. Cystone (500 mg/kg, p.o.) was used as reference standard 
drug.Ethylene glycol–ammonium chloride feeding caused an increase in urinary 
volume, oxalate, total protein, phosphate and uric acid levels, along with a 
decrease in urinary excretion of calcium, magnesium and citrate. 
Supplementation with MBS significantly prevented change in the urinary 
excretion of calcium, oxalate, phosphate, total protein, uric acid, magnesium 
and citrate and also prevented the elevation of serum creatinine, uric acid and 
blood urea nitrogen levels. The increased calcium, oxalate,lipid peroxidation 
and   phosphate levels in the kidney of lithiatic control rats were significantly 
reduced by the MBS supplementation. Histological study revealed minimum 
damage and less number of calcium oxalate deposits in the kidneys of MBS- 
treated rats.These results indicated that the MBS reduced and prevented the 
growth of urinary stones.
46
 
 
 
Dixit et al., (2014) designed a study to evaluate the effect of Crashcal, a 
polyherbal formulation in the treatment of renal calculi. The urolithiasis was 
induced by ethylene glycol. Oxalate, calcium and phosphates were monitored in 
the urine and kidney. Serum BUN, creatinine and uric acid were also recorded. 
In-vivo antioxidant parameters such as lipid peroxidation (MDA), glutathione 
(GSH) and superoxide dismutase (SOD), catalase (CAT), body weight, kidney 
weight and urine volume were also monitored.  In hypercalculi animals, the 
oxalate, calcium and phosphate excretion grossly increased. However, the 
increased deposition of stone forming constituents was significantly lowered by 
Crashcal. It was also observed that Crashcal produced significant decrease in
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MDA   and   increased   GSH,   SOD   and   CAT.   Thus   they   reported   the 
antiurolithiatic activity of Crashcal.
47
 
 
Soundararajan  et al., (2014) investigated the anti urolithiatic activity of various 
extract   of   whole   plant   of   Ageratum   conzoidesLinn   on   experimentally 
urolithiasis induced male albino wistar rats. Urolithiasis was induced in animals 
by using ethylene glycol (5% v/v, 2ml/rat/7days). Experimental induction of 
hyperoxaluria results in rapid formation of calcium oxalate crystals in the renal 
tubules of experimental animals. Investigation was done on the basis of 
estimation of stone forming constituents oxalate, calcium, and phosphate, in 
kidney and urine. The results proved that the calcuri, ethanolic extracts and 
ethyl  acetate  extract  significantly  lowered  the  increased  levels  of  oxalate, 
calcium and phosphate in urine and also significantly reduced their retention in 
kidney. 
48
 
 
 
Dharmalingam et al., (2014) reported the anti-urolithiatic activity of the aqueous 
and alcoholic extracts of Melia azedarach Linn leaves in calcium oxalate 
urolithiasis in male albino rats. Lithiasis was induced by oral administration of 
ethylene glycol (0.75 %v/v) in male albino rats for 28 days. Each of the extract 
(250 mg/kg) was administered orally on day 0 as a prophylactic regimen and 
from day 15 as a curative regimen. Regular administration of ethylene glycol 
caused hyperoxaluria in ethylene glycol-fed animals, leading to increased renal 
retention and excretion of oxalate, calcium and phosphate.  Histopathological 
study, urine microscopy, serum analysis and biochemical analysis of kidney 
homogenate were performed. Oxalate and calcium excretion in urine increased 
respectively, in lithiatic control animals compared to (0.37 ± 0.01 and 1.27 ± 
0.12 mg/24 h) for the normal control group. Treatment with aqueous or ethanol 
extract significantly (p <0.01) reduced the elevated levels of calcium, oxalate 
and phosphate excretion in urine to 0.79 ± 0.01 and 1.09 ± 0.04 mg/24 h, 
respectively. Histopathological data for the kidney supported the foregoing 
results.
49
 
 
Thangarathinam  et al.,(2013) reported the effect of Polyherbal Syrup (Aqueous 
decoction of Aerva lanata, Astercantha longifolia, Cucumis sativus, Cumimum 
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cyminum, Hemides  musindicus,  Lagenaria  siceraria  and  Tribulus  terrestris) 
against ethylene glycol–induced urolithiasis in male Wistar albino rats . 
Urolithiasis was induced in rats by administering 0.75% ethylene glycol in 
drinking water for 28 days and was manifested by high urinary calcium, 
phosphorus and low urinary volume, pH, magnesium content and high uric acid, 
creatinine, urea and BUN in serum. Simultaneous administration of Polyherbal 
syrup  (100  and  200  mg/kg/oral)  and  standard  drug  hydrochlorothiazide 
150µg/kg orally for 28 days along with ethylene glycol (0.75%) reduced urinary 
calcium, phosphorus and increased urinary volume, pH and magnesium and 
reduced uric acid, creatinine, urea and BUN in serum. The histopathological 
studies confirmed the induction of urolithiasis as microcrystal deposition 
observed in sections of kidney from animals treated with ethylene glycol. This 
was reduced after treatment with the Polyherbal syrup.
50
 
 
 
Bhaskar et al.,(2012) evaluated   the effect of ethanolic extract of Nymphaea 
alba linn on urolithiatic rats .The urolithiasis was induced by inserting zinc disc 
(a foreign body) in the urinary bladder followed by supplementing 1% ethylene 
glycol in drinking water. The reduction in weight of the stones was used as 
criteria for assessing the preventive or curative regimen. Ethanolic extract of 
dried leaves of Nymphaea alba Linn was administered orally. It was studied by 
administering two different doses of the plant for prophylactic and curative 
groups.  Oral  administration  of  the  Nymphaea  alba  Linn  has  resulted  in 
significant reduction in the weight of bladder stones compared to the control 
group.
51
 
 
Lin et al., (2012) aimed to investigate the effects of Flos catharmi on calcium 
oxalate (CaOx) formation in ethylene glycol (EG)-fed rats. For all experimental 
animals, 24-h urine and blood samples were analyzed at the beginning and end 
of the experiment.  Kidney tissue  was  histopathologically examined  using a 
polarized  light  microscope,  and  crystal  deposits  were  evaluated  by a semi- 
quantitative scoring method; these scores were significantly lower in the FC 
groups (600 and 1,200 mg/day) than in the placebo group. Thus, they reported 
the antilithiatic effect of Flos catharmi.
52
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Paras    et  al.,(2012)evaluated  the  saponin  rich  fraction  prepared  from  fruits 
of Solanum xanthocarpum (SXS) for antiurolithiatic activity by in vitro and in 
vivo studies. Lithiasis was induced by oral administration of ethylene glycolated 
water (0.75%). Various biochemical parameters in urine, serum and kidney 
homogenate were analysed after 28 days. Kidneys were also subjected to 
histopathological analysis. The lithogenic treatment caused polyuria, renal 
function damage and oxidative stress, manifested as increased malondialdehyde, 
depleted reduced glutathione and decreased antioxidant enzyme catalase 
activities of the kidneys, were prevented by simultaneous administration with 
SXS. 
53
 
 
Sathya et al., (2012) reported the antilithiatic activity of the ethanolic extract of 
roots of Saccharum spontaneum Linn.in rats. Lithiasis was induced by oral 
administration of ethylene glycolated water (0.75%) in adult male wistar albino 
rats for 28 days. The ionic chemistry of urine was altered by ethylene glycol 
(EG), which elevated the urinary concentration of crucial ions, viz. calcium, 
phosphorus and protein thereby contributing to renal stone formation. A 
significant reduction in the elevated level of these ions in urine of the extract 
treated animal marked the antiurolithiatic activity of the plant.
54
 
 
 
Sathish et al., (2010) studied the antilithiatic effect of Hygrophila spinosa on 
ethylene glycol induced lithiasis in male albino rats. The lithiasis was induced to 
rats by oral consumption of ethylene glycolated water (0.75v/v) for 28 days. 
Aqueous extract of H. spinosa (200mg/kg) was administered orally from 1st day 
for preventive regimen and from 15th day for curative regimen. The parameters 
assessed were the calcium, oxalate, inorganic phosphate, protein concentration 
in urine. The H.spinosa significantly (P<0.01) reduced the elevated levels of 
these ions and protein in urine and significantly (P<0.01) elevated the urinary 
concentration ofmagnesium. The elevated serum creatinine levels of lithiatic 
rats were reduced by prophylactic and curative regimen of extract treatment. 
Thehistological  findings  also  showed  improvement  after  treatment  with  the 
extract. 
55
 
 
Yogendr et al., (2009) studied the effect of oral administration of aqueous and 
alcohol extracts of Jasminum auriculatum Vahl (Oleaceae) flowers on calcium 
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oxalate nephrolithiasis  in male albino rats. Ethylene glycol feeding resulted in 
hyperoxaluria as well as increased renal excretion of calcium and phosphate.A 
significant reduction in the elevated urinary oxalate, showing a regulatory action 
on endogenous oxalate synthesis was observed in the extract treated group. The 
curative and preventive treatment using aqueous and alcohol extracts also 
decreased the increased deposition of stone forming constituents in the kidneys 
of calculogenic rats. The results indicate that the flowers of J. auriculatum are 
endowed with antiurolithiatic activity.
56
 
 
 
NEPHROTOXICITY 
 
Nephrotoxicity (from Greek: nephros,"kidney") is a poisonous effect of some 
substances, both toxic chemicals and medication, on the kidneys. There are 
various forms of toxicity. It is one of the most common kidney problems and 
occurs when body is exposed to a drug or toxin. When kidney damage occurs, 
body unable to rid of excess urine and wastes from the body and blood 
electrolytes (such as potassium and magnesium) will all become elevated. A 
number of therapeutic agents can adversely affect the kidney resulting in acute 
renal failure, chronic interstitial nephritis and nephritic syndrome because 
increasing number of potent therapeutic drugs. The nephrotoxic effect of most 
drugs is more profound in patients who already suffer from renal impairment. 
Some drugs may affect renal function in more than one way. 
 
Nephrotoxic agents 
 
Drugs, diagnostic agents & chemical are well known to be nephrotoxic. The 
following are some of the important nephrotoxic agents. 
A.  Heavy metals                    :       Mercury, arsenic, lead, bismuth 
 
B. Antineoplastic agents      :       Alkylating agents, Cisplatin, 
Cyclophosphamide, Antimetabolites, 
Antitumor antibiotics 
C.  Antimicrobial agents        :       Tetracycline, Acyclovir, Rifampicin 
 
D.   Amino glycosides            :       Gentamicin, Amikacin, Kanamycin, 
(Tubular cell toxicity)                   Streptomycin 
E.   Miscellaneous                  :        Non-steroidal anti-inflammatory 
Ibuprofen, Indomethacin
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The nephrotoxins damage specific segment of the nephron to a greater extent 
than the other segments. The proximal tubule is the most commonly affected, 
because of the presence of inducible type of microsomal mixed function oxidase 
(cytochromeP-450)  which  have  been  implicated  in  the  toxic  activation  of 
various agents. This segment is also rich in glutathione and glutathione 
metabolizing enzymes. The other common sites which can be affected are renal 
medulla, distal tubule and Loop of Henle. The renal medulla is affected mainly 
by polyene antibiotics and cyclosporine and that of distal tubule dysfunction is 
mainly  due  to  non-steroidal  anti-inflammatory  agents,  cyclosporine, 
pentamidine, trimethoprim, sulphamethaxozole, amphotericin,amino glycoside 
antibiotics, lithium, and demeclocycline.The functional manifestations of 
nephrotoxicity can occur at several levels like tubular function abnormalities 
such as potassium, magnesium and sodium wasting, concentrating defects and 
reduction in glomerular filtration. However, there are no ideal clues to the 
occurrence or localization of tubular cell injury. The nephrotoxins induced 
changes in the tubule cells may be lethal or sub lethal. 
 
In the present study we are adopting cisplatin induced nephrotoxic model. 
 
 
CISPLATIN IDUCED NEPHROTOXOCITY 
 
Cisplatin (cis-diamminedichloroplatinum II, CP) is a highly effective 
antineoplastic DNA alkylating agent   used against a diverse spectrum of 
malignancies 
57 
Although higher doses of cisplatin are more efficacious for the 
treatment  of  cancer,  many reversible  and  irreversible  side  effects  including 
nephrotoxicity,  neurotoxicity,  bone  marrow  toxicity,  gastrointestinal  toxicity 
and ototoxicity often limit its utility and therapeutic profile 
58,59
. Primary targets 
of cisplatin in kidney are proximal straight and distal convoluted tubules where 
it  accumulates  and  promotes  cellular  damage,  by  multiple  mechanisms 
including oxidative stress, DNA damage and apoptosis.
60,61
Several lines of 
evidence  suggest  the  role  of  ROS  in  the  pathogenesis  of  nephrotoxicity. 
Cisplatin induces free radical production causing oxidative renal damage, 
possibly due to depletion of non-enzymatic and enzymatic antioxidant 
systems.
62,63
 
Light  and  electron  microscopy have shown  that  the CP-induced  injury and 
necrosis in the rat kidney are predominantly localized in S3 sub segments of 
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+ 
proximal tubular epithelial cells. Morphologically, it is characterized by the loss 
of  microvilli,  cellular  swelling  and  condensation  of  nuclear  chromatin  .
64
 
Mitochondrial lysosomes and microsomes are critical CP targets .
65,66 
Functional 
 
alterations are characterized by change in urine volume, increase in blood urea 
nitrogen and serum creatinine .
67
There is a continuous search for agents that 
provide nephroprotection against CP and other platinum drugs. These include 
antioxidants, modulators of nitric oxide, diuretics, and cytoprotective and 
apoptotic agents. However, none of these were found to be suitable/safe for 
clinical use in protecting against CP-induced nephrotoxicity.
68
 
 
 
Mechanism of action of Cisplatin 
 
It is generally accepted that binding of cisplatin (CDDP) to genomic DNA 
(gDNA) in the cell nucleus is the main event  responsible for its antitumor 
properties. Once CDDP has been intravenously administered to the patient; it 
rapidly diffuses into tissues and is highly bound to plasma proteins. Binding of 
CDDP to plasma proteins is a result of the strong reactivity of platinum against 
sulphur of thiol groups of amino acids such as cysteine. Hence, near 90% of the 
platinum in the blood is bound to albumin and other plasma proteins leading to 
inactivation of a great amount of cisplatin. Loss of the chloride groups from the 
cisplatin  molecule  is  required  before  it  binds  to  gDNA.  Outside  the  cell, 
chloride concentration is around 100 mM. However, within the cell, chloride 
concentrations range between 2 and 30 mM and cisplatin aquation occurs. 
Consequently, water molecules replace one or both chloride leaving groups. The 
result       is       the       formation       of       the       [Pt(H2O)Cl(NH3)2]+       and 
[Pt(H2O)2(NH3)2]2  cations. These mono and diaquo species of cisplatin are very 
reactive towards nucleophile centres of biomolecules because H2O is a much 
better leaving group than Cl
-
. 
 
Several lines of evidence suggest that mitochondrial DNA, or other 
mitochondrial targets, are perhaps more important than nuclear DNA damage in 
mediating cisplatin-induced cell death. Cisplatin is hydrolysed to generate a 
positively charged metabolite which preferentially accumulates within the 
negatively charged mitochondria. Thus, the sensitivity of cells to cisplatin 
appears to correlate with both the density of mitochondria.
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Pathophysiology 
 
Cisplatin Uptake and Accumulation in Renal Cells 
 
Uptake of cisplatin is mainly through the organic transporter pathway.  The 
kidney accumulates cisplatin to a greater degree than other organs and is cleared 
by the kidney by both glomerular filtration and tubular secretion .The cisplatin 
concentration in proximal tubular epithelial cells is about 5 times the serum 
concentration suggesting an active accumulation of drug by renal parenchymal 
cells.   The   disproportionate   accumulation   of   cisplatin   in   kidney   tissue 
contributes to cisplatin-induced nephrotoxicity. 
69
 
 
Glomerular filtration, and to a lesser extend secretion are the predominant 
excretion routes for cisplatin in the rats. No evidence supports the tubular 
reabsorption.  Cisplatin  is  accumulated  by  peritubular  uptake  in  both  the 
proximal and distal nephrons. The S3 segment of the proximal tubule 
accumulates the highest concentration of cisplatin, followed by the distal 
collecting tubule and the S1 segment in the proximal tubule. In addition to a 
transporter-mediated    process,cisplatin    enters    the    cell    through    passive 
diffusion.
70
The contribution of active uptake by a transport system and passive 
 
diffusion through the cellular membrane may vary at different sites. 
 
In  general, two different membrane transporters are capable of  transporting 
cisplatin into cells: Ctr1 and OCT2. Ctr1 is a copper transporter which was also 
shown  to  mediate  cisplatin  uptake  into  mammalian  cells  including  ovarian 
cancer cells. Ctr1 is highly expressed in adult kidney and the protein localizes to 
the basolateral  membrane of the proximal  tubule. Down  regulation  of Ctr1 
expression in kidney cells in vitro decreased both cisplatin uptake and 
cytotoxicity, suggesting that Ctr1 is an important cisplatin uptake mechanism in 
these cells.
71
Transporter mediated uptake is likely the major pathway in renal 
 
cells.
72
The organic cation transporter (OCT 2) is the critical transporter for 
cisplatin uptake in proximal tubules in both animals and humans. Transport 
mediated by these membrane proteins is polyspecific, electrogenic, voltage- 
dependent,   bi-directional,   pH-independent,   and   Na
+
-independent.   Three 
isoforms of OCT have been identified in humans. OCT2 is the main OCT in the 
kidney, OCT1 is the main isoform of the liver, and OCT3 is widely expressed,
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especially in the placenta. Cisplatin is not transported through human OCT1, 
which may help explain its organ-specific toxicity. Carboplatin and oxaliplatin, 
the less nephrotoxic analogues of cisplatin, have no interaction with human 
OCT2.
73
Cimetidine, an organic cation competitor for the transport at human 
OCT2,  reduces  cisplatin  induced  proximal  tubule  cell  apoptosis.
74
Diabetic 
animals have reduced gene and protein expression of OCT isotypes and are 
resistant to cisplatin toxicity. 
 
 
Cisplatin Metabolism 
 
Conversion of cisplatin to nephrotoxic molecules in the proximal tubule cells is 
required  for  cell  injury.  The  highest  concentration  of  cisplatin  is  found  in 
cytosol, mitochondria, nuclei, and microsomes. 
75 
Cisplatin undergoes metabolic 
activation in the kidney to a more potent toxin. This process begins with the 
formation of glutathione conjugates in the circulation, perhaps mediated by 
glutathione-S-transferase.
76,77
As the glutathione-conjugates pass through the 
kidney, they are cleaved to cysteinyl-glycine-conjugates by gamma glutamyl 
transpeptidase (GGT) expressed on the surface of the proximal tubule cells . 
The cysteinyl-glycine-conjugates are further metabolized to cysteine-conjugates 
by aminodipeptidases, also expressed on the surface of the proximal tubule 
cells. The cysteine-conjugates are transported into the proximal tubule cells, 
where they are further metabolized by cysteine-S-conjugate beta-lyase which is 
an  intracellular  enzyme  to  highly  reactive  thiols.
78,79
Inhibiton  of  gamma 
glutamyl transpeptidase (GGT) and cysteine-S-conjugate beta-lyase enzymes 
has no effect on the uptake of cisplatin into the kidney but reduces 
nephrotoxicity. Inhibition of gamma glutamyl transpeptidase activity, however, 
renders cisplatin inactive as an antitumor drug.
80
 
Cisplatin  can  form  monohydrated  complexes  by  hydrolytic  reactions.  The 
 
monohydrated complex is more toxic to the renal cells than cisplatin but it is not 
kidney specific. The normal low intracellular chloride concentrations promote 
its formation. Using hypertonic saline to reconstitute cisplatin can decrease the 
amount   of   monohydrated   complex   formed.   This   approach   attenuates 
nephrotoxicity but may also compromise its antitumor activity.
81
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Cellular Targets of Cisplatin 
 
Platinum compounds are believed to mediate their cytotoxic effects through 
their interaction with DNA.  In an aqueous environment, the chloride ligands of 
cisplatin are replaced by water molecules generating a positively charged 
electrophile. This electrophile reacts with nucleophilic sites on intracellular 
macromolecules to form DNA, RNA and protein adducts.
82
Cisplatin binds to 
DNA leading to the formation of inter- and intrastrand cross-links, thereby 
arresting DNA synthesis and replication in rapidly proliferating cells.
82  
The 
finding that cells deficient in DNA repair are more sensitive to cisplatin-induced 
cell death supports the concept that cisplatin mediates its anti-tumor effects 
through DNA damage. However, the primacy of nuclear DNA damage as the 
cause of cisplatin-induced cell death has been challenged. In fact, only a small 
amount of cellular platinum (<1%) is bound to nuclear DNA and there is a poor 
correlation between the sensitivity of cells to cisplatin-induced cell death and 
the extent of DNA platination.
83
 
Several lines of evidence suggest that mitochondrial DNA, or other 
mitochondrial targets, are perhaps more important than nuclear DNA damage in 
mediating cisplatin-induced cell death
.84
Cisplatin is hydrolysed to generate a 
positively charged metabolite which preferentially accumulates within the 
negatively charged mitochondria. Thus, the sensitivity of cells to cisplatin 
appears to correlate with both the density of mitochondria and the mitochondrial 
membrane potential 
85,86
. This observation may explain the particular sensitivity 
of the renal proximal tubule to cisplatin toxicity, as this segment exhibits one of 
the highest densities of mitochondria in the kidney. 
Mitochondrial energetics is also disrupted by cisplatin and may contribute to 
nephrotoxicity. Fatty acids are the major source of energy for the proximal 
tubule, the primary site of cisplatin kidney injury. Cisplatin inhibits fatty acid 
oxidation in mouse kidney and in proximal tubule cells in culture through a 
reduction in PPAR-α mediated expression of genes involved in cellular fatty 
acid utilization. Cisplatin also affects mitochondrial respiratory complexes and 
function. 
87,88
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Biochemical Changes in the Renal Cell 
 
Cisplatin induces specific gene changes. Genes involved in drug resistance, in 
cytoskeleton structure and function , in cell adhesion , in apoptosis , in tissue 
remodeling and in detoxification are upregulated after cisplatin-induced injury. 
Genesdownregulated by cisplatin include those that localize to the proximal 
tubules, those that control intracellular calcium homeostasis and those that 
encode growth factors or their binding proteins. These gene changes are 
associated with cisplatin damage to proximal tubules, tissue remodeling, and 
regeneration. 
89,90
 
 
Cisplatin-induced  nephrotoxicity  is  mediated  by  mitogen-activated  protein 
kinase (MAPK) intracellular signalling pathways. The MAPK pathways are a 
series of parallel cascades of serine/threonine kinases that are activated by 
diverse extracellular physical and chemical stresses. They regulate cell 
proliferation, differentiation and survival. The 3 major MAPK pathways 
terminate in the extracellular regulated kinase (ERK), p38 and Jun N-terminal 
kinase/stress-activated protein kinase (JNK/SAPK) enzymes. The ERK pathway 
is typically activated by extracellular growth factors and has been linked to both 
cell survival and cell death. ERK and p38 function as an upstream signal 
stimulating tumor necrosis factor-α (TNF-α) production. ERK also activates 
caspase 3, which controls apoptosis in renal tubular cells. Phosphorylated-ERK 
is exclusively localized in the distal nephron; therefore ERK1/2 activation may 
mediate distal nephron injury P38 activation mediates proximal tubule cells 
injury. 
 
 
Intracellular Changes That Damages Renal Cell 
 
The in vivo mechanisms of cisplatin nephrotoxicity are complex and involve 
oxidative stress, apoptosis, inflammation, and fibrogenesis. High concentrations 
of cisplatin induce necrosis in proximal tubule cells, whereas lower 
concentrations induce apoptosis through a caspase-9–dependent pathway 90,91. 
The major pathways in cisplatin-induced acute tubular cell injury are shown 
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Figure 7 : Major pathways in cisplatin-induced acute tubular cell injury 
 
 
 
Role of free radical species 
 
Oxidative stress injury is actively involved in the pathogenesis of cisplatin- 
induced acute kidney injury. Reactive oxygen species (ROS) directly act on cell 
components, including lipids, proteins and DNA and destroy their structure. 
ROS are produced via the xanthine-xanthine oxidase system, mitochondria and 
NADPH  oxidase  in  cells.  In  the  presence  of  cisplatin,  ROS  are  produced 
through all these pathways and are implicated in the pathogenesis of acute 
cisplatin-induced renal injury. Cisplatin induces glucose-6-phosphate 
dehydrogenase and hexokinase activity, which increase free radical production 
and decrease antioxidant production. It increases intracellular calcium level 
which activates NADPH oxidase and to stimulates ROS production by damaged
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mitochondria. Free radicals can also cause mitochondrial dysfunction
92
.Reactive 
nitrogen species have also been studied in cisplatin-induced nephrotoxicity. The 
renal content of peroxynitrite and nitric oxide is increased in cisplatin treated 
rats which causes changes in protein structure and function, lipid peroxidation, 
chemical cleavage of DNA and reduction in cellular defences by oxidation of 
thiol pools. 
93
 
 
 
Hypoxia and mitochondrial injury 
 
Pathological changes in cisplatin-induced nephrotoxicity occur mainly in the S3 
segment of the proximal tubule in the outer stripe of the outer medulla. This 
zone of the kidney is more susceptible to ischemic insult and injury to this 
segment occurs in other toxic acute renal failure model 
94  
. Hypoxic tubules in 
the outer medulla have been identified by pimonidazole staining in cisplatin 
nephrotoxicity. Analyses using serial sections indicate that a significant portion 
of hypoxic cells are proximal tubular cells. Therefore, hypoxia may have an 
important role in cisplatin-induced nephrotoxicity, and this probably develops 
during the decreased renal blood observed during the initial phase of cisplatin 
nephrotoxicity. However, hypoxia inducible factor 1(HIF-1) is activated in the 
S3 segment of proximal tubules in cisplatin injury in vivo. HIF-1 is a 
transcription factor that mediates cellular responses to hypoxia, including 
angiogenesis, erythropoiesis and glycolytic adaptation. Dominant negative HIF- 
1 α-subunit animals have increased susceptibility to cisplatin injury mediated by 
apoptosis which was associated with the increased release of cytochrome c, loss 
of mitochondrial membrane potential, and increased caspase 9 activities. 
Therefore, the net effect of hypoxia in cisplatin-induced renal injury is 
uncertain.95 
 
 
Apoptosis 
 
The mechanisms of cisplatin-induced nephrotoxicity are complex and involve 
multiple pathways 
96  
. The cellular pathways of cisplatin injury to kidney cells 
have been examined primarily in vitro using freshly isolated or cultured renal 
tubular epithelial cells. In vitro, low concentrations of cisplatin preferentially 
result in apoptotic cell death while at higher concentrations necrosis ensues
97 
.In
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vivo administration of nephrotoxic doses of cisplatin produces a large increase 
in both necrosis and apoptosis in the kidney. Several apoptotic pathways have 
been implicated in cisplatin-induced renal epithelial cell death, including the 
extrinsic pathway activated through death receptors, such as TNF receptors or 
Fas, the intrinsic mitochondrial pathway and the endoplasmic reticulum stress 
pathway. Death receptor pathways may be activated by cisplatin include 
observations that TNFR1 and Fas-deficient renal epithelial cells are resistant to 
cisplatin-induced cell death    that cisplatin increases the activity of caspase 8 
and that inhibition of caspase 8 reduces cisplatin-induced cell death in vitro 
98,99,100
.TNF-α stimulates an inflammatory response in vivo which exacerbates 
 
cisplatin nephrotoxicity
101  
.Thus, exposure of renal epithelial cells to cisplatin 
results in the translocation of Bax to mitochondria, activation of caspase 2, 
release of cytochome c, AIF,SMAC/Diablo, Omi/HtrA2 and endonuclease G 
from mitochondria and activation of caspase 9 
102
. Caspases are a family of cell 
death proteases that play an essential role in the execution phase of apoptosis in 
cisplatin  induced  renal  tubular  epithelial  cell  death  in  vitro  and  in  vivo. 
Activation of caspases 3, 8 and 9 occur as early as 12 hours after cisplatin 
treatment of renal epithelial cells in vitro and inhibition of caspase activity 
suppresses cisplatin induced cell death . Both  p53 dependent expression of 
caspases 6 and 7 and p53-independent activation of caspases through Bax/Bak 
mediated release of cytochrome C   contribute to cisplatin induced tubular 
epithelial cell death
103,104 
.The ER stress pathway involves activation of caspase 
12 and Ca
2+  
dependent phospholipase A2 and pharmacological inhibition of 
 
these enzymes reduces cisplatin-induced apoptosis. Finally, autophagy has 
recently been shown to participate in cisplatin-induced cell injury. 
Cisplatin injury can be ameliorated by free radical scavengers, iron chelators, 
superoxide dismutase, catalase, selenium and Vitamin E and heme oxygenase-1 
induction  
104,105
.  In  summary,  cisplatin-induced  renal  cell  death  involves 
multiple pathways including oxidant stress, activation of intrinsic and extrinsic 
apoptotic cascades and endonucleases (Figure 8). Unfortunately, many of these 
same pathways contribute to the cytotoxic actions of cisplatin on tumor cells. 
Therefore, strategies intended to reduce cisplatin renal injury may have the
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unintended consequence of reducing the anti-tumor actions of cisplatin. The 
design of preventive strategies must carefully consider this risk. 
 
 
 
 
Figure 8 :Apoptotic pathways activated by cisplatin in renal tubular cells. 
 
 
 
Inflammation in cisplatin nephrotoxicity 
 
Cisplatin induces a series of inflammatory changes that mediate renal injury. 
Recent evidences indicate that inflammation has an important role in the 
pathogenesis of cisplatin-induced renal injury. Cisplatin-induced injury to renal 
epithelial cells causes release of DAMPs, which activate TLR4. Activation of 
TLR4 results in the production of a variety of chemokine‟s and cytokines, 
including TNF-α. These chemokine‟s and cytokines up regulate adhesion 
molecules and attract inflammatory cells, such as neutrophils and T cells, into 
the region of injury. Tissue resident dendritic cells act to reduce kidney injury, 
at least in part by producing the anti-inflammatory cytokine IL-10. Treg cells 
also reduce kidney injury although the mechanism is still unknown. Dendritic 
cells also enhance the number or activity of Treg cells. 
107,108
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Figure 9 : Immune mechanisms of cisplatin nephrotoxicity. 
 
 
 
In summary, cisplatin causes direct tubular injury through multiple mechanisms. 
Significant interactions among these various pathways may occur during this 
injury. For example, TNF-α induces apoptosis, produces ROS, and coordinates 
the activity of a network of cytokines that all contribute to cellular injury. 
However, it  also  triggers the expression  of  inducible nitric oxide synthase, 
increases  the  production  of  nitric  oxide  and  enhances  HIF-1  activity  in 
normoxic renal  tubule  cells,  events  that  could  limit  injury.How much  each 
pathway and the interactions among these pathways contribute to the cisplatin 
nephrotoxicity has not been determined. 
 
 
Reported Activity on Nephroprotective Activity of Herbs. 
 
Tilyek et al., (2016) investigated the nephroprotective effects of Ribes 
diacanthum Pall (RDP) against cisplatin-induced nephrotoxicity. 
Nephroprotection of RDP was investigated by oral administration of RDP 
aqueous extract at a daily dose of 40mg/kg for14 consecutive days, starting 7 
days prior to cisplatin administration.RDP treatment significantly reduced blood 
urea nitrogen (BUN) and serum creatinine (Cr) level in cisplatin-administrated 
mice.   Histopathological   analysis   demonstrated   that   RDP   administration 
protected  cisplatin-induced  renal  tubular  cell  apoptosis.  Hence  reported  the 
nephroprotective effect of Ribes diacanthum.
109
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Mohamed et al.,(2016) aimed to determine whether nebivolol possesses a 
protective effect against cisplatin nephrotoxicity and explore many mechanisms 
underlying this potential effect. Nephrotoxicity was induced in Wistar rats by a 
single intraperitoneal injection of cisplatin (6 mg/kg) on day 2. Nebivolol (10 
mg/kg) was administered orally for 7 consecutive days. Nebivolol showed a 
nephroprotective effect  as demonstrated by the significant reduction in the 
elevated levels of serum creatinine and urea as well as renal levels of 
malondialdehyde, nitric oxide products (nitrite/nitrate), inducible nitric oxide 
synthase,   tumour   necrosis   factor-alpha,   caspase-3,   angiotensin   II   and 
endothelin-1 with a concurrent increase in renal levels of reduced glutathione 
and endothelial nitric oxide synthase compared to untreated rats. 
Histopathological examination confirmed the nephroprotective effect of 
nebivolol. Pre-treatment with Nω-nitro-L-arginine methyl ester, the non-specific 
nitric oxide synthase inhibitor partially altered the protection afforded by 
nebivolol. In conclusion, nebivolol protects rats against cisplatin-induced 
nephrotoxicity that is most likely through its antioxidant, anti-inflammatory 
and antiapoptotic effects as well as by abrogation of the augmented angiotensin 
II and endothelin-1 levels.
110
 
 
 
 
Sindhu et al., (2015) investigated the nephroprotective effect of vanilic acid 
against cis-platin induced nephrotoxicity in male wistar rats. Elevated levels of 
serum creatinine, bloodurea nitrogen, serum uric acid and reduced antioxidant 
status were observed as indicatives of nephrotoxicity in cisplatin (7 mg/kg bw) 
alone administered rats. Animals which are pre-treated with vanillic acid (50 
mg/kg and 100 mg/kg) restored the elevated levels of renal function markers 
and reduced antioxidant status to near normalcy when compared to cis-platin 
alone  treated  animals.  Cisplatin  induced  lipid  peroxidation  was  markedly 
reduced by oral administration of vanillic acid at a high dose. The findings in 
the present study suggest that vanillic acid is a potential antioxidant that reduce 
cisplatin nephrotoxicity and can be used as a combinatorial regimen in cancer 
chemotherapy.
111
 
 
 
KanchanGaikwad et al., (2013) designed a study to investigate the potential 
nephroprotective activity of 250mg/kg and 500mg/kg of ethanolic extract of
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Adiantum  capillus-veneris  dried  fronds  against  Cisplatin  induced  oxidative 
stress caused in male Wistar rats. Acute nephrotoxicity was induced by i.p. 
injection  of  Cisplatin  (7  mg/kg  of  body  weight  (b.w.)).  Administration  of 
ethanol  extract  at  dose  level  of  500  and  250  mg/kg  (b.w.)  to  Cisplatin 
intoxicated rats (toxic control) for 14 days attenuated the biochemical and 
histological  signs  of  nephrotoxicity of  Cisplatin  in  dose-dependent  fashion. 
Ethanol extract at 500 mg/kg decreased the serum level of creatinine and urea as 
compared to the toxic control group. The ethanol extract of Adiantum capillus- 
veneris at 500 mg/kg (b.w.) exhibited significant and comparable 
nephroprotective potential. The statistically (one-way-ANOVAfollowed by 
Dunnet‟s test)  processed  results  suggested  the  positive  action  of  Adiantum 
capillus-veneris Cisplatin induced nephropathy.
112
 
 
 
 
Sarawoot et al., (2013) investigated the possible protective role of curcumin and 
α-tocopherol against cisplatin induced nephrotoxicity in rat. Male Wistar rats 
were divided into five groups. Groups 1 and 2 were intraperitoneally (i.p.) 
injected with normal saline and cisplatin (20 mg/kg), respectively. Groups 3, 4 
and  5  were  pre-treated  with  a  single  dose  of  α-tocopherol  (250  mg/kg), 
curcumin (200 mg/kg) and α-tocopherol with curcumin, respectively, for 24 h 
prior  to  the  administration  of  cisplatin.  After  72  h  following  injection, 
specimens were collected. Serum blood urea nitrogen (BUN), creatinine and 
malondialdehyde (MDA) levels, superoxide dismutase (SOD) and catalase 
activities, kidney histopathological study and gene expressions of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase and p38 mitogenactivated 
protein kinase (p38-MAPK) were investigated. Pre-treatment with combined 
curcumin and α-tocopherol exhibited significantly reduced MDA levels and 
enhanced activities of SOD and catalase compared with cisplatin-treated group 
(p < 0.05).  It  also  improved  BUN  as  well  as  creatinine levels  and  kidney 
histopathology.   Moreover,   gene   expressions   of   NADPH   oxidase   were 
decreased, whereas p38-MAPK gene expressions were not significant compared 
with cisplatin-treated group.
113
 
 
 
Priyadarsini et al.,(2012) evaluated   the Avuri kudineer[Decoction of Indigo 
feratinctoria] made of indigo leaves AKL, the Avuri kudineermade of indigo
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root and leaves AKR  for nephron protective activity in Cisplatin induced renal 
damage  in  rats.  Nephrotoxicity was  induced  in  wistar  albino  rats  by intra- 
peritoneal administration of Cisplatin 5mg/kg. Effect of concurrent 
administration of AKL and AKRL Avuri kudineer at a dose of 500 mg/kg and 
1000mg/kg were given for respective animal groups by oral route was 
determined using serum creatinine and blood urea and change in body weight as 
indicators  of  kidney  damage.  The  decoctions  significantly  decreased  the 
cisplatin induced nephrotoxicity. Remarkable changes were observed in body 
weight, serum creatinine and urea levels. It was observed that the Avuri 
kudineer[AKRL] significantly protected the kidneys from injury than the Avuri 
kudineer[AKL].
114
 
 
 
 
Shelke et al., (2009) Reported the nephroprotective activity of the   ethanolic 
extract of dried fruits of  Pedalium murex  in Cisplatin induced renal damage in 
rats. Nephrotoxicity was induced in Wistar rats by intraperitoneal administration 
of Cisplatin 5mg/kg. Effect of concurrent administration of the ethanolic extract 
at a dose of 250 mg/kg given by oral route was determined using serum 
creatinine and blood urea and change in body weight as indicators of kidney 
damage. Cystone was used as standard drug. The extract significantly decreased 
the cisplatin  induced  nephrotoxicity.  Remarkable changes  were observed  in 
body  weight,  serum  creatinine  and  urea  levels.  It  was  observed  that  the 
ethanolic extract significantly protected the kidneys from injury.
115
 
 
 
Nitha et al.,(2008) explored the protective effect of the aqueous-ethanol extract 
of cultured mycelium of M. esculenta against cisplatin and gentamicin induced 
acute renal toxicity in Swiss albino mice. Cisplatin and gentamicin when 
administered induced a marked renal failure, characterized by a significant 
increase in serum urea and creatinine concentrations. Treatment with various 
concentration of extract decreased the cisplatin and gentamicin induced increase 
in serum creatinine and urea levels and also restored the depleted antioxidant 
defense system. The decreased activity of superoxide dismutase (SOD), catalase 
(CAT), glutathione peroxidase (GPx), and reduced glutathione (GSH) in the 
kidneys consequent to cisplatin and gentamicin administration was significantly 
elevated.
116
Gaurav et al., (2007) evaluated the aqueous extract of Kalanchoe 
pinnata for its protective effects on gentamicin-induced nephrotoxicity in rats. 
Page 55 
 
 
Effect of concurrent administration of K. pinnata leaf extract at a dose of 125 
mg/kg/day given  by  intraperitoneal  route  was  determined  using  serum  and  
urinary creatinine and blood urea nitrogen as indicators of kidney damage and 
they observed that the aqueous extract of K. pinnata leaves significantly protects 
rat kidneys from gentamicin-induced histopathological changes. Gentamicin- 
induced glomerular congestion, peritubular and blood vessel congestion, 
epithelial desquamation, accumulation of inflammatory cells and necrosis of the 
kidney cells were found to be reduced in the group receiving the leaf extract of 
K. pinnata along with gentamicin. This extract also normalized the gentamicin- 
induced increases in urine and plasma creatinine, blood urea and blood urea 
nitrogen levels .
117
 
 
 
Annie  et  al.,  (2005)  studied  the  ethanolic  extract  of  the  roots  of  Cassia 
auriculata for its nephroprotective activity in cisplatin- and gentamicin-induced 
renal injury in male albino rats. In the cisplatin model, the extract at doses of 
300 and 600 mg/kg body wt. reduced elevated blood urea and serum creatinine 
and normalized the histopathological changes in the curative regimen. In the 
gentamicin model, the ethanol extract at a dose of 600 mg/kg body wt. reduced 
blood urea and serum creatinine effectively in both the curative and the 
preventive regimen. The extract had a marked nitric oxide free-radical- 
scavenging effect. The findings suggest that the probable mechanism of 
nephroprotection by C. auriculata against cisplatin- and gentamicin-induced 
renal  injury  could  be  due  to  its  antioxidant  and  free-radical-scavenging 
property.
118
 
 
 
Shirwaikar et al.,(2003) studied the protective effect of  various concentrations 
of ethanolic extract of Pongami apinnata flowers against cisplatin and 
gentamicin induced nephrotoxicity in rats.The activity was assessed by 
measuring the loss of body weight ,elevated blood urea,  serum creatinine levels 
and various Histopathological studies.The extract  normalized the body weight , 
raised blood urea and serum creatinine levels.Reversal of   cisplatin and 
gentamicin  renal  cell  damage  as  induced  by  tubular  necrosis  ie,  marked 
congestion of the glomeruli with glomerular atrophy, degeneration of tubular 
epithelial cells with casts in the tubular lumen and infiltration of inflammatory 
cells in the interstitium was confirmed on histopathological examination.
119
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Plan of work 
 
 
Scores of drugs in common clinical use are capable of inflicting various degrees 
of damage to the kidney. Similarly, a large number of widely employed 
chemicals may adversely affect renal tissue as part of their toxic potential. 
Urolithiasis and nephrotoxicity are two common kidney problems faced by the 
global population.Urolithiasis is one of the major diseases of the urinary tract 
and  is  a major source  of morbidity.  Stone formation  is  one of the painful 
urologic disorders and it is estimated that 12% of world population experiences 
renal stone disease with a recurrence rate of 70-80% in men and 47-60% in 
women and in economically developed countries the prevalence rate ranged 
between 4% and 20%.
6, 7
. 
 
 
Nephrotoxicity is another major common kidney problem which occurs when 
the body is exposed to a drug or toxin. Cisplatin, a platinum compound, is one 
of the most potent chemotherapeutic agent available to treat a variety of 
malignancies, including ovarian, lung, head, and neck cancers, as well as 
testicular and bladder tumors.Unfortunately, cisplatin induces cumulative and 
dose-dependent  nephrotoxicity,  which  restricts  the  use  of  high  doses  to 
maximize the therapeutic efficacy. Approximately, one third of patients 
experience renal dysfunction after treatment with cisplatin 
 
Even though kidney stone and nephrotoxicity was categorized among the most 
prevalent and widespread disease in the world, till date no guaranteed cure is 
found for the same. None of the known and available treatments prevent the 
reoccurrence  of  kidney  stone  formation  and  toxicity produced  by cisplatin. 
Hence the dire need for the herbal formulation appears to be the need of the 
hour. With the above consideration the study is focused to find a herbal remedy 
for urolithiasis and nephrotoxicity caused by cisplatin. 
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METHODOLOGY 
 
 
A.PLANT MATERIALS 
 
 
A.1.Collection and identification of the plant materials 
 
 
The plant Helicanthes elastica (Loranthaceae) growing on Mangifera indica 
(Anacardiaceeae) were collected during the month of September –October from 
ABS Botanical Garden, Kaaripatti, Salem District, Tamilnadu. The  mistletoe 
was authenticated by A.Balasubramaniyam, Executive Director, ABS Botanical 
Garden, Salem. 
 
A.2. Preparation of methanolic extract of Helicanthes elastica 
 
 
The collected plant materials were washed with water to remove the dirt and 
other materials and then dried under shade. After confirming the dryness of the 
plant material, they were grounded with a mechanical grinder to get a coarse 
powdered plant material and then extracted with methanol using Soxhlet 
extraction apparatus. The methanol (80%) extract was concentrated using rota 
vapour under vacuum pressure. 
 
A3) Preliminary phytochemical screening 
 
 
The qualitative phytochemical screening was performed on the methanolic 
extract of HE for the qualitative determination of phytochemical constituents 
such as alkaloids, flavonoids, phenolic compounds, tannins, steroids, terpenoids, 
carbohydrates, saponins, glycosides, proteins and diterpenes using standard 
procedures. 
 
Detection of Carbohydrates 
 
 
a)Molisch’s test 
 
 
Test  extract  was  dissolved in  1ml  of distilled water and  added  2  drops  of 
 
alcoholic α-naphthol solution in a test tube and added 2ml of Conc. sulphuric
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acid carefully along the sides of the test tube.The formation of violet ring at the 
junction indicates the presence of carbohydrates. 
 
b)Benedict’s Test 
 
 
Mixed equal volumes of the Benedict‟s reagent and the test extract and  heated 
on a water bath.The formation of orange red precipitate indicates the presence 
of reducing sugars. 
 
c)Fehling’s Test 
 
 
The extract was hydrolysed with HCl, Neutralized with alkali and heated with 
Fehling‟s A  and  B  solutions.The  formation  of  red  precipitate  indicates  the 
presence of reducing sugars 
 
Detection of proteins 
 
 
a)Biuret test 
 
 
Treated a small amount of the   extract with 4%(w/v) NaOH and 1% (w/v) 
CuSO4 .The formation of violet colour indicate the presence of protein. 
 
b)Ninhydrin test 
 
 
0.5ml of the  extract was treated with  3 drops of Ninhydrin reagent  and boiled 
for few minutes.Formation of blue colour indicate the presence of protein. 
 
Detection of alkaloids. 
 
 
a)Dragendroff’s  test 
 
 
The  extract  was  treated  with  Dragendroff‟s reagent  (solution  of  potassium 
bismuth  iodide). The formation  of red  precipitate indicates  the presence of 
alkaloids. 
 
b)Mayer’s Test 
 
 
The extract was treated with Mayer‟s reagent (Potassium mercuric iodide ) and 
 
the formation of yellow precipitate indicate the presence of alkaloids.
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c)Wagner’s Test 
 
 
 
 
The extract was treated with Wagner‟s reagent (iodine in potassium iodide) and 
the formation of brown or reddish brown precipitate  indicates the presence of 
alkaloid. 
 
d)Hager’s Test 
 
 
The extract was treated with Hager‟s reagent (saturated picric acid solution). 
 
The formation of yellow coloured precipitate indicate the presence of alkaloids. 
 
 
Detection of glycosides 
 
 
a)Keller kiliani test 
 
 
2 ml of glacial acetic acid containing one drop of ferric chloride solution was 
added to 0.5 ml of extract diluted with 5 ml water. This was underlayed with 1 
ml of concentrated sulphuric acid. A brown ring at the interface indicated the 
presence  of  a  deoxysugar  characteristic  of  cardenolides.  A  violet  ring  may 
appear below the brown ring, while in the acetic acid layer a greenish ring may 
form just above the brown ring and  gradually spread  throughout this layer 
which indicates the presence of cardiac glycosides. 
 
b)Bromine water test 
 
 
The extract was treated with bromine water.The formation of yellow colour 
indicates the presence of glycosides. 
 
c)Legal’s test 
 
 
The extract was treated with sodium nitroprusside in pyridine and methanolic 
alkali.The  formation  of  pink  to  red  blood  colour  indicates  the  presence  of 
cardiac glycosides.
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a) Alkaline reagent test 
 
 
The extract  was  treated  with  few drops  of NaOHsolution.The formation  of 
intense yellow colour that becomes colourless on addition of few drop of dilute 
acid indicates the presence of flavonoids. 
 
b) Lead acetate test 
 
 
The extract was treated with few drops of lead acetate solution.The formation of 
yellow colour indicates the presence of flavonoids. 
 
c)Shinoda test 
 
 
To an alcoholic solution of the extract , few pieces of magnesium chips were 
added followed by a few drops of concentrated hydrochloric acid .The 
appearance of an orange, pink or red to purple colour indicates the presence of 
flavonoids. 
 
Detection of phenolic compounds 
 
 
a)Ferric chloride test 
 
 
The extract was treated with few drops of ferric chloride solution. Observed for 
the formation of brownish green or bluish black colour indicates the presence of 
phenolic compounds. 
 
Detection of tannins 
 
 
a)Ferric chloride test 
 
 
0.5ml of  extract was boiled in 10ml of water and filtered. To the filtrate added 
few drops of 0.1% ferric chloride solution.The formation of brownish green or 
bluish black colour indicates the presence of phenolic compounds. 
 
b)Gelatin test 
 
 
To the extract added 1% gelatin solution containing sodium chloride. Observed 
for the formation of white precipitate which indicates the presence of tannins.
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Lead acetate solution was added to the extract.The formation of yellow colour 
indicates the presence of tannins. 
 
Detection of saponins 
 
 
a)Foam test 
 
 
0.5ml of the extract was shaken with 5ml  of water and then checked for the 
foam formation that persist for ten minutes which indicates the presence of 
saponins. 
 
Detection of steroids and triterpenoids 
 
 
a)Salkowski’s test 
 
 
2ml of the extract was dissolved in 2ml of chloroform and filtered. The filtrate 
was  then treated  with  few drops  of conc.  Sulphuric acid,  shaken  well  and 
allowed to stand for few minutes.The formation of reddish brown colour 
indicates the presence of steroids/terpenes. 
 
b)Liebermann Buchard’s  test 
 
 
The extract was treated with chloroform and filtered.The filtrate was treated 
with few drops of acetic anhydride, boiled and cooled. Observed for the 
formation of brown ring at the junction that indicates the presence of steroids / 
terpenes. 
 
B.Experimental Animals and Exposure conditions 
 
 
Healthy Wistar rats of either sex weighing about 180-250g procured from the 
Government veterinary animal house, Mannuthy, approved by  the Committee 
for the   Purpose   of Control and Supervision of Experiments on Animals 
(CPCSEA)   were used     for the study.The   study was approved by the 
Institutional Animal Ethic Committee of the institute.The rats were housed in 
standard polypropylene cages with stainless steel top grill and reared at the 
animal house of  Padmavathi College of Pharmacy, Dharmapuri.  Paddy  husk  
was  used  as bedding which was changed at least thrice in a week.Six rats were 
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housed per cage. All the animals received human care according to the criteria 
outlined in the “Guide for the Care and Use of Laboratory Animas” prepared by 
the “National  Institute  of     Health”.  All  the  procedures  were  performed  in 
accordance with the Institutional Animal Ethics Committee constituted as per 
the direction of the by Committee for the  Purpose  of Control and Supervision 
of Experiments on Animals (CPCSEA), under the ministry of animal welfare 
division, Government of India, New Delhi, India. 
 
The animals were kept in a clean environment with 12 hours light and 12 hours 
dark cycles.   The temperature was maintained at 25±3
o
C and the relative 
humidity was maintained at 45±5%. Animals were fed ad libitum with normal 
laboratory chow standard pellet diet and drinking water in polypropylene bottles 
with  a  stainless  steel  sipper  tube  throughout  the  study.  The  animals  were 
selected randomly. All the animals were acclimatized for 7 days prior to the 
commencement of the experiment. 
 
C) Instruments 
 
 
Digital colorimeter (SYSTRONICS) 
 
 
High speed refrigerated centrifuge (KEMI) 
Micro centrifuge (SPINWIN) 
Digital balance (SHIMADZU AY220) 
UV-Spectrometer (SHIMADZU 1700) 
Vertical laminar air flow (KEMI) 
BOD incubator (ROTEK) 
Hot air oven (KEMI) 
Autoclave (KEMI) 
D.DrugsAnd Chemicals 
Ethylene glycol (Sigma)
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Cystone (Himalaya) 
Cisplatin 
Tween 80 
 
 
Ethyl ether 
 
 
E.SelectionOf Dose 
 
 
Dose selected for the present was based on the acute toxicity studies conducted 
by  M  S  Rajesh  on  the  metanolic  fractions  of  Helicanthes  elastica.
15
They 
reported that neither death nor any observable neuro behavioural effects were 
observed in the limit test.Hence as stated in OECD guideline no 425,these 
compounds were classified as globally harmonized system (GHS) category-5 
substances.Due to the lack of any observable toxicity at the 2000mg/kg dose, 
LD50was  not  determined.So  two  doses were chosen to  carryout  the present 
study.The  two  doses  were  chosen  in  such  a  way that,  the  first    dose  was 
approximately   1/10
th    
of   the   maximum   dose   administered   during   acute 
toxicities(i.e.,1/10
th  
of 2000mg/kg body weight- 200mg/kg body weight) and a 
 
high dose which was twice that of 1/10
th 
dose i.e.,400mg/kg body weight . 
 
 
F.EXPERIMENTAL DESIGN 
 
 
F.1.In- vivo methods-Anti urolithiatic activity 
 
 
For the assessment of antiurolithiatic activity, two dose levels 200mg/kg and 
 
400mg/kg were chosen. Male Wistar rats were elected from the entire group of 
animals and grouped in different cages.The dried crude methanolic extracts of 
whole plant of Helicanthes elastica were suspended in 5% tween 80 for oral 
administration. Antiurolithiatic activity was performed using Ethylene Glycol 
Induced Urolithiaisis rat models having curative and preventive treatment 
schedules. 
 
Ethylene Glycol Induced Urolithiasis Model
46,47,48
 
 
 
The experimental animals were divided into eight groups (n=6) to study the 
curative and preventive effect of the methanolic extract of Helicanthes elastica 
on ethylene glycol induced urolithiasis in rats. 
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Group I (Normal control) - Animals were fed with regular rat food and 
drinking water ad libitum from day 1 to 28. 
 
0.75% ethylene glycol with 1% w/v ammonium chloride in drinking water ad 
libitum for a period of 3 days to accelerate lithiasis followed by only 0.75% v/v 
ethylene glycol for next 25 days was fed to group II to group VIII for induction 
of renal calculi. 
 
Group II (Toxic control) - Animals received 0.75% ethylene glycol in drinking 
water till 28
th 
day. 
 
Preventive treatment 
 
 
Group III (standard)- Animals received daily single oral dose of standard 
antiurolithiatic drug Cystone (750mg/kg) first day  till  28
th 
day 
 
Group IV - Animals received a single oral dose of the plant extract (200mg/kg 
body weight p.o)   from first day till 28
th 
day. 
 
Group V - Animals received a single oral dose of the   plant extract (400mg/kg 
body weight p.o) from first day till 28
th 
day. 
 
Curative treatment 
 
 
Group VI (Standard) - Animals received daily single oral dose of standard 
antiurolithiatic drug Cystone (750mg/kg) from 15
th 
day till 28
th 
day. 
 
Group VII - Animals received a single oral dose of the plant extract (200mg/kg 
body weight p.o) from 15
th 
day till 28
th 
day. 
 
Group  VIII  -  Animals  received  a  single  oral  dose  of  the      plant  extract 
 
(400mg/kg body weight p.o)  from 15
th 
day till 28
th 
day. 
 
 
On day 28 animals of all the groups were kept in metabolic cages and urine 
samples were collected for 24 hours and analysed for calcium, magnesium and 
total standard methods. The animals are anaesthetized using ethyl ether and 
blood samples were collected by cardiac puncturing and serum creatinine, blood 
urea nitrogen and uric acid were analysed. The urinary output volumes of all 
groups  were  also  noted.  The  animals  were  sacrificed  under  ethyl  ether 
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anaesthesia and the kidneys are isolated and carried out the Histopathological 
studies. 
 
F.2.In vivo methods- Nephroprotective activity 
 
 
Cisplatin induced nephrotoxicity model
114
 
 
 
The experimental animals were divided into five groups (n=6) to study the 
curative  effect  of  methanolic  extract  of  Helicanthes  elastica  on  cisplatin 
induced renal toxicity in rats. 
 
Group I (Normal control) – Animals received daily oral dose of the vehicle 
 
(CMC 0.6%w/v) from day 1 to day 15(10ml/kg body weight, p.o). 
 
 
Group II (Toxic control) – Animals were administered with single i.p. dose of 
cisplatin 5mg/kg body weight on day 1. 
 
Group III (Standard group)-Animals were administered with single i.p dose 
of cisplatin 5mg/kg body weight on day 1 and Cystone 500mg/kg body weight 
orally from day 2 till 14. 
 
Group IV – Animals received a single i.p dose of cisplatin 5mg/kg body weight 
on day 1, followed by daily a single oral dose of the plant extract (200mg/kg 
body weight, p.o) from day 2 to 14. 
 
Group V – Animals received a single i.p dose of cisplatin 5mg/kg body weight 
on day 1, followed by daily a single oral dose of the plant extract (400mg/kg 
body weight, p.o) from day 2 to day 14. 
 
On day 15, animals of all the groups were anasthetised using ethyl ether and the 
blood samples were collected by cardiac puncture and serum creatinine, total 
protein and blood urea nitrogen were analysed. The animals are sacrificed at the 
end of the study and isolated the kidneys and carried out the Histopathological 
studies on the samples. 
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G.BIOCHEMICAL ESTIMATION 
G.1.MAGNESIUM 
120
 
Principle 
 
 
Magnesium ions react with xylidyl blue in an alkaline medium to form purple 
coloured complex. The intensity of the purple colour is directly proportional to 
the concentration of magnesium in the specimen. 
Mg
2+ 
+ Xylidyl blue→                               Magnesium-Xylidyl blue complex
 
Calcium is excluded from the reaction by complexing with ethylene glycol tetra 
 
acetic acid. 
 
 
Procedure 
 
 
Prewarm at room temperature the required amount of reagent before use. 
 
 
 
Sample Standard Blank 
 0.01ml 0.01ml - 
Reagent 1.0ml 1.0ml 1.0ml 
 
 
 
Incubation 
 
Incubate the assay mixture for 5 minutes at 37
ο
C.After the incubation measure 
the absorbance of assay mixture against blank at 546nm.Final colour is stable 
for 30 minutes if not exposed to direct light. 
 
Calculation 
Magnesium in mg% =  (                                       )
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G.2.CALCIUM
120,121
 
 
 
Principle 
 
 
Calcium forms a purple coloured complex with cresolphthaleincomplexone in 
alkaline medium. This complex absorbs light at 575(570-580) nm. The intensity 
of the colour is directly proportional to the calcium concentration in specimen. 
Calcium + cresolphthaleincomplexone→                   purple colour
 
Procedure 
 
Prewarm  at  room  temperature  (25-30
ο
C)  the  required  amount  of  working 
solution. Perform the assay as given below. 
 
 
 
Sample standard Blank 
 0.02ml 0.02ml - 
Working solution 1.0ml 1.0ml 1.0ml 
 
 
 
Incubation 
 
 
Mix and keep the assay mixture for 5 minutes at room temperature(25- 
 
30
ο
C).Measure the absorbance against blank at 575nm.(570-580nm).Final 
colour is stable for one hour if not exposed to direct light. 
 
Calculation
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G.3.CREATININE 
122
 
 
 
Principle 
 
 
Creatinine in alkaline medium reacts with picrate to produce orange colour.This 
colour absorbs light at 492nm.(490-510nm).The rate of increase in absorbance 
is directly proportional to the concentration of creatinine in specimen. 
Creatinine + Picrate→                          Orange colour 
Procedure 
 
 
Standard/sample 0.05ml 
Working solution 1.0ml 
 
 
 
Mix and aspirate.After the initial delay of 30 seconds record the absorbance of 
the test at an interval of 60seconds at 492nm.Determine the mean change in 
absorbance and calculate the test results. 
 
Calculation 
 
 
 
(                                                     ) 
 
 
 
G.4.TOTAL PROTEIN 
123
 
 
 
Principle 
 
 
Protein reacts with cupric ions under alkaline pH to produce a colour complex. 
This colour complex absorbs light at 546nm.(530-570nm).The intensity of the 
colour is directly proportional to the protein concentration in specimen. 
Protein →                                                           Blue colour complex
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Procedure  
Prewarm  at  room  temperature  (25-30
ο  
C)  the  required  amount  of  working 
solution before use. 
 
Perform the assay as given below 
 
 
 Sample Standard Blank 
 0.01ml 0.01ml - 
Working Solution 1.0ml 1.0ml 1.0ml 
 
 
 
Incubation 
 
Incubate  the  assay  mixture  for  5  minutes  at  37
ο
C.  After  completion  of 
incubation period measure the absorbance of specimen  against blank.  Final 
colour is stable for 8hours if not exposed to direct light. 
 
Calculation 
(                                                  )
 
G.5.URIC ACID 
121,123
 
 
 
Principle 
 
 
Uricase converts uric acid into allantoin and hydrogen peroxide.In presence of 
peroxidase, hydrogen peroxide oxidatively couples with phenolic chromogens 
to  form  a  red  coloured  compound,  which  has  maximum  absorbance  at 
510n.(500-530nm).The concentration of the red coloured compound is 
proportional to the amount of uric acid in specimen. 
Uric acid +H2O→             Allantoin +H2O2
 
H2O2 + Phenolic chromogen→                  Red colour compound
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Procedure  
Prewarm at room temperature (25-30
o
C) the required amount of reagent before 
use. 
 
Perform the assay as given below 
 
 
 Sample Standard Blank 
 0.025ml 0.025ml - 
Reagent 1.0ml 1.0ml 1.0ml 
 
 
 
Incubation 
 
Incubate the  assay mixture for 5  minutes  at  37
o  
C  or 10  minutes  at  room 
temperature.  After completion  of the incubation  measure the absorbance of 
assay mixture against blank at 510nm.Final colour is stable for 30 minutes if not 
exposed to direct light. 
 
Calculation
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RESULTS 
 
 
1. Preparation of Crude Extract 
 
 
Crude methanolic extract of the whole plant of Helicanthes elastica was 
prepared by soxhlet extraction with methanol (hydro alcoholic mixture (20:80). 
 
2.Preliminary Phytochemical Screening of Extract 
 
 
The results of preliminary phytochemical screening of MHE are given below in 
the table. The MHE extract revealed the presence of carbohydrates, sterols, 
terpenoids, flavones, phenols, tannins and glycosides. 
 
Table 3: Results of Phytochemical Screening 
 
 
 
 
Sl.No 
 
 
Test 
 
 
Inference 
1 
 
a. 
b. 
c. 
Carbohydrates 
 
Mollisch‟s test 
Benedict‟s test 
Fehling‟s test 
 
 
+ 
 
+ 
 
+ 
2 
 
a. 
b. 
Proteins and aminoacids 
 
Biuret test 
 
Ninhydrin test 
 
 
_ 
 
_ 
3 
 
a. 
b. 
c. 
d. 
Alkaloids 
 
Mayer‟s test 
Wagner‟s test 
Hager‟s test 
Dragendorff‟s test 
 
 
_ 
 
_ 
 
_ 
 
_ 
4 
a. 
b. 
c. 
Glycosides 
 
Keller kiliani test 
Legal‟s test 
Bromine water test 
 
 
+ 
 
+ 
 
+ 
5 
 
a. 
Flavanoids 
 
Alkaline reagent test 
 
 
+ 
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b. 
 
c. 
Lead acetate test 
 
Schinoda test 
+ 
 
+ 
6 
 
a. 
Phenols 
 
Ferric chloride test 
 
 
+ 
7 
 
a. 
b. 
c. 
Tannins 
 
Ferric chloride test 
 
Gelatin test 
 
Lead acetate test 
 
 
+ 
 
+ 
 
+ 
8 
 
a. 
Saponins 
 
Foam test 
 
 
_ 
9 
 
a. 
b. 
Steroids and triterpenoids 
 
Salkowski‟s test 
 
Liebermann Buchard‟s test 
 
 
 
+ 
+ 
Key: + indicates the presence of constituents 
 
- indicates the absence of constituents 
 
 
 
ANTIUROLITHIATIC ACTIVITY 
H.1.Determination of body weight 
The determination of body weight of all rats in different groups before and after 
 
study period shows that, the normal control (Group I) rats increased their body 
weight. The standard group (Group III and Group IV) maintained their weight 
with a very little variation. The test group (Group IV) has not much weight loss 
when compared with the toxic group (Group II) of rats. Results are shown in 
table 4and graph 1. 
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Table 4 : Mean ± SEM of body weight determination 
 
 
GROUPS BODY WEIGHT Mean ±  SEM (g) 
Before study After study 
Group I Normal control 179.465±4.3254 175.23±6.2354 
Group II Toxic control 170.66±4.3547 160.67±4.2465 
Group III Preventive standard 178.667±5.2147 174.235±6.3214 
Group IV Preventive 
 
200mg/kg 
181.365±5.2454 176.547±1475 
Group V Preventive 
 
400mg/kg 
179.166±3.4568 171.894±4.8741 
Group VI Curative standard 174.166±5.2458 171.235±5.4758 
Group VII Curative 200mg/kg 182.356±4.5641 174.23±6.1452 
Group VIII Curative 400mg/kg 176.14±3.847 171.235±3.4574 
 
 
 
Effect of MHE on body weights of rats 
 
 
185 
 
180 
 
175 
170 
 
165 
 
160 
 
 
Before study 
 
After study
 
155 
 
150 
145  
Group 1 Group 2 Group3 Group 4 Group 5 Group 6 Group 7 Group 8
 
 
Graph 1: Body weights of rats before and after study period 
 
 
Group1: Normal control; Group 2: Toxic control; Group 3: Preventive standard; 
Group 4:Preventive 200mg/kg; Group 5: Preventive MHE 400mg/kg; Group 6:
Page 77 
 
 
 
Curative standard; Group 7: Curative MHE 200mg/kg;  Group8: Curative MHE 
 
400mg/kg 
 
 
H.2.Urine output determination 
 
 
Rats were kept in individual metabolic cages for 24 hours for urine collection on 
 
28
th  
day of the study. The normal control rats did not show any significant 
variation in the urinary output level throughout the experimental period. The 
urine output was found to increase significantly (P< 0.001) by ethylene glycol 
treated group. Results are shown in table5 and graph 2 
 
Table 5: Statistical analysis of urine output 
 
 
GROUPS URINE OUTPUT(ml/24 
 
hr) 
Group I Normal control 8.56±0.2403 
Group II Toxic control 6.00±0.1125*** 
Group III Preventive standard 8.31±0.1492*** 
Group IV Preventive MHE 200mg/kg 8.55±0.1477*** 
Group V Preventive MHE 400mg/kg 9.33±0.2728*** 
Group VI Curative standard 8.05±0.3271*** 
Group VII Curative MHE 200 mg/kg 8.66±0.1967*** 
Group VIII Curative MHE 400mg/kg 8.89±0.6685*** 
 
 
 
All the values are expressed as Mean ± SEM (n=6) 
 
P values *** for P<0.001; ** for P<0.01; * for P<0.05 
 
Values of Group II were compared with Group I and those of Group III to V 
with Group II.
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Graph 2: Effect of MHE on urine volume 
 
 
H.3.SERUM PARAMETERS 
 
Creatinine, Blood urea nitrogen and uric acid are the important markers for 
assessment of effect on kidney function. 
 
H.3.1.Effect on Serum Creatinine 
 
 
Serum  creatinine  level  of  the  control  and  experimental  rats  on  last  day of 
experiment are shown in Table 6. The serum creatinine level of the normal 
control  rats  (Group  I)  was  0.90  ±  0.1437mg/dl,  while  it  was  significantly 
elevated to 2.50 ± 0.2569mg/dl in animals treated with ethylene glycol (Group 
II) with a significance level of P<0.001. 
In the preventive regimen, the animals which received standard drug, Cystone 
 
750mg/kg(Group  III)  significantly  reduced  the  creatinine  levels    to  0.93  ± 
 
0.2996mg/dl   and in Curative regimen , the animals which received standard 
drug, Cystone 750mg/kg (Group VI) significantly reduced the creatinine levels 
to 1.06 ± 0.2458mg/dl. The statistical result showed, Group III and Group VI 
reduced the serum creatinine levels at a significance of P<0.001 and P<0.01 
respectively.
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In the preventive regimen, the animals which received MHE at doses of 200 
and 400 mg/kg body weight (Group IV and Group V) significantly reduced the 
serum creatinine level to1.26 ± 0.2044g/dl and 0.96 ± 0.1891mg/dl respectively. 
The statistical result showed, Group IV and Group V reduced the serum 
creatinine levels at a significance of P<0.01 and P<0.001 respectively. 
Similarly in curative regimen, the animals which received MHE at doses 200 
and 400 mg/kg body weight (Group VII and Group VIII) significantly reduced 
the  serum  creatinine  to  1.40  ±  0.1932mg/dl  and  1.16  ±  0.3559  mg/dl 
respectively when compared with toxic control (Group II).The statistical result 
showed, Group VI and VIII reduced the serum creatinine levels at a significance 
of P<0.05 and P<0.01 respectively. 
 
 
H.3.2. Effect on Serum Blood Urea Nitrogen 
 
Serum blood urea nitrogen level of the control and experimental rats on last day 
of experiment are shown in Table 6. The serum blood urea nitrogen level of the 
normal control rats (Group I) was 37.51 ± 1.0514 mg/dl, while it was 
significantly elevated to 52.53 ± 1.4812mg/dl in animals treated with ethylene 
glycol (Group II) with a significance of P<0.001. 
In the preventive regimen, the animals which received standard drug, Cystone 
 
750mg/kg(Group III) significantly reduced the blood urea nitrogen levels   to 
 
42.91 ± 1.4639 and in Curative regimen , the animals which received standard 
drug, Cystone 750mg/kg (Group VI) significantly reduced the blood urea 
nitrogen levels  to  44.86 ± 1.8529mg/dl. The statistical result showed, Group III 
and Group VI reduced the serum BUN levels at a significance of P<0.001 and 
P<0.01 respectively. 
In the preventive regimen, the animals which received MHE at doses of 200 
and 400 mg/kg body weight (Group IV and Group V) significantly  reduced the 
serum  blood  urea  nitrogen  level     to  48.75  ±  1.6186mg/dl  and  43.56  ± 
1.1532mg/dl respectively.The statistical result showed, Group V reduced the 
serum BUN levels at a significance of P<0.001. 
Similarly in curative regimen, the animals which received MHE at doses 200 
and 400 mg/kg body weight (Group VII and Group VIII) significantly reduced 
the serum blood urea nitrogen   to 48.86 ± 1.4663mg/dl and 45.29   ± 0.8443
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mg/dl respectively when compared with toxic control (Group II).The statistical 
result showed, Group VIII reduced the serum BUN levels at a significance of 
P<0.01. 
H.3.3 Effect on Serum Uric acid 
 
 
Serum uric acid level of the control and experimental rats on last day of 
experiment  are  shown  in  Table  6.  The  serumuric  acid  level  of  the  normal 
control  rats  (Group  I)  was  1.88  ±  0.1603mg/dl,  while  it  was  significantly 
elevated to 3.97 ± 0.0227mg/dl in animals treated with ethylene glycol (Group 
II) with a significance level of P<0.001. 
In the preventive regimen, the animals which received standard drug, Cystone 
 
750mg/kg(Group  III)  significantly  reduced  the  uric  acid  levels    to  2.52  ± 
 
0.3557mg/dl   and in Curative regimen , the animals which received standard 
drug, Cystone 750mg/kg (Group VI) significantly reduced the uric acid levels 
to 2.75 ± 0.2366mg/dl. The statistical result showed, Group III and Group VI 
reduced the serum uric acid levels at a significance of P<0.01. 
In the preventive regimen, the animals which received MHE at doses of 200 
and 400 mg/kg body weight (Group IV and Group V) significantly reduced the 
serum  uric  acid  level  to  3.48  ±  0.1959mg/dl  and  2.60  ±  0.2081mg/dl 
respectively. The statistical result showed, Group V reduced the serum uric acid 
levels at a significance of  P<0.01. 
Similarly in curative regimen, the animals which received MHE at doses 200 
and 400 mg/kg body weight (Group VII and Group VIII) significantly reduced 
the  serum    uric  acid    to  3.75  ±  0.3207mg/dl  and  2.94  ±  0.2271  mg/dl 
respectively when compared with toxic control (Group II).The statistical result 
showed, Group VIII reduced the serum uric acid level at a significance of 
P<0.05.
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Table 6 : Serum parameters of rats used in antiurolithiatic study 
 
 
 
Groups 
 
Treatment 
Serum 
Creatinine 
mg/dl 
Serum Blood 
Urea Nitrogen 
mg/dl 
 
Uric Acid 
mg/dl 
 
 
Group I 
 
 
Normal control 
 
 
0.90± 0.143 
 
 
37.51±1.051 
 
 
1.88±0.160 
 
Group 
II 
 
 
Toxic control 
 
 
2.50±0.256*** 
 
 
52.53±1.481 *** 
 
 
3.97±0.227*** 
 
Group 
III 
 
P
re
v
e
n
ti
v
e
 t
re
a
tm
e
n
t 
 
 
Standard 
 
 
0.93±0.299*** 
 
 
42.91±1.463 *** 
 
 
2.52±0.355** 
 
Group 
IV 
 
 
200mg/kg 
 
 
1.26±0 .204** 
 
 
48.75±1.618 
 
 
3.48±0.195 
 
Group 
V 
 
 
400mg/kg 
 
 
0.96± 0.189*** 
 
 
43.56±1.153 *** 
 
 
2.60±0.208** 
 
Group 
VI 
 
C
u
r
a
ti
v
e
 t
re
a
tm
e
n
t 
 
 
Standard 
 
 
1.06±0.245** 
 
 
44.86±1.852 ** 
 
 
2.75±0.236** 
 
Group 
VII 
 
 
200mg/kg 
 
 
1.40±0.193* 
 
 
48.86±1.466 
 
 
3.75±0.320 
 
Group 
VIII 
 
 
400mg/kg 
 
 
1.16±0.355** 
 
 
45.29±0.844 ** 
 
 
2.94±0.227* 
 
 
 
All the values are expressed as Mean ± SEM (n=6) 
 
P values *** for P<0.001; ** for P<0.01; * for P<0.05 
 
Values of Group II were compared with Group I and those of Group III to V 
with Group II.
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I.4.URINE PARAMETERS 
I.4.1. Effect on Calcium 
Calcium level of the control and experimental rats on last day of experiment are 
shown in Table 7. The calcium level of the normal control rats (Group I) was 
4.92 ± 0.4135mg/dl, while it was significantly elevated to 9.54 ± 0.04839mg/dl 
in animals treated with ethylene glycol (Group II) with a significance level of 
P<0.001. 
In the preventive regimen, the animals which received standard drug, Cystone 
 
750mg/kg(Group  III)  significantly  reduced  the  calcium  levels    to  5.60  ± 
 
0.3455mg/dl   and in Curative regimen , the animals which received standard 
drug, Cystone 750mg/kg (Group VI) significantly reduced the calcium levels  to 
5.83 ± 0.5171mg/dl. The statistical result showed, Group III and Group VI 
 
reduced the calcium levels at a significance of P<0.001. 
 
In the preventive regimen, the animals which received MHE at doses of 200 
and 400 mg/kg body weight (Group IV and Group V respectively) significantly 
reduced the calcium level to 8.93 ± 0.7202mg/dl and 5.98 ± 0.4755mg/dl 
respectively. The statistical result showed, Group V reduced the calcium levels 
at a significance of P<0.001. 
Similarly in curative regimen, the animals which received MHE at doses 200 
and 400 mg/kg body weight (Group VII and Group VIII) significantly reduced 
the calcium to 8.10 ± 0.6145mg/dl and 6.81 ± 0.8215 mg/dl respectively when 
compared with toxic control (Group II).The statistical result showed, Group 
VIII reduced the calcium level at a significance of  P<0.01.
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I.4.2. Effect on Magnesium 
 
 
Magnesium level of the control and experimental rats on last day of experiment 
are shown in Table 7. The magnesium level of the normal control rats (Group I) 
was  2.93±  0.2133mg/dl,  while  it  was  significantly  decreased  to  0.87  ± 
0.3022mg/dl in animals treated with ethylene glycol (Group II) with a 
significance level of P<0.001. 
In the preventive regimen, the animals which received standard drug, Cystone 
 
750mg/kg(Group III) significantly increased the magnesium levels   to 2.21 ± 
 
0.1151mg/dl   and in Curative regimen , the animals which received standard 
drug,  Cystone 750mg/kg (Group VI) significantly increased the magnesium 
levels   to 2.19 ± 0.3038mg/dl. The statistical result showed, Group III and 
Group VI increased the magnesium levels at a significance of P<0.001 
andP<0.01 respectively. 
In the preventive regimen, the animals which received MHE at doses of 200 
and 400 mg/kg body weight (Group IV and Group V respectively) significantly 
increased the magnesium level to 1.45 ± 0.1146mg/dl and 2.16 ± 0.8596mg/dl 
respectively. The statistical result showed, Group V increased the magnesium 
levels at a significance of P<0.01. 
Similarly in curative regimen, the animals which received MHE at doses 200 
and 400 mg/kg body weight (Group VII and Group VIII) significantly increased 
the magnesium to 1.51 ± 0.3674mg/dl and 2.10 ± 0.0573 mg/dl respectively 
when   compared   with   toxic   control   (Group   II).The   statistical   result 
showed,Group VIII increased the magnesium level at a significance of P<0.01.  
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I.4.3. Effect on Total protein 
Total  protein  level  of  the  control  and  experimental  rats  on  last  day  of 
experiment are shown in Table 7. The total protein level of the normal control 
rats (Group I) was 2.12 ± 0.1459g/dl, while it was significantly elevated to 5.60 
± 0.1843g/dl in animals treated with ethylene glycol (Group II) with a 
significance level of P<0.001. 
In the preventive regimen, the animals which received standard drug, Cystone 
 
750mg/kg(Group III) significantly reduced the total protein levels   to 2.60 ± 
 
0.2331g/dl  and in Curative regimen , the animals which received standard drug, 
Cystone 750mg/kg (Group VI) significantly reduced the total protein levels  to 
2.87  ±  0.2871g/dl.  The  statistical  result  showed,  Group  III  and  Group  VI 
 
reduced the total protein levels at a significance of P<0.001. 
 
In the preventive regimen, the animals which received MHE at doses of 200 
and 400 mg/kg body weight (Group IV and Group V respectively) significantly 
reduced the total protein level to 4.21 ± 0.2458g/dl and 2.87 ± 0.2271g/dl 
respectively. The statistical result showed, Group V reduced the total protein 
levels at a significance of  P<0.001. 
Similarly in curative regimen, the animals which received MHE at doses 200 
and 400 mg/kg body weight (Group VII and Group VIII) significantly reduced 
the total protein to 4.39 ± 0.3232g/dl and 3.15 ± 0.1735 g/dl respectively when 
compared with toxic control (Group II).The statistical result showed, Group VII 
and Group VIII reduced the total protein level at a significance of  P<0.01 and 
P<0.001 respectively.
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Table 7: Urine parameters of rats used in antiurolithiatic study 
 
 
 
Groups 
 
Treatment 
Calcium 
mg/dl 
Magnesium 
mg/dl 
Total Protein 
g/dl 
 
 
Group I 
 
 
Normal control 
 
4.92±0.4135 
 
2.93±0.2133 
 
2.12±0.1459 
 
Group II 
 
Toxic control 
 
9.54±0.483*** 
 
0.87±0.302*** 
 
5.60±0.184*** 
 
Group 
III 
 
P
re
v
e
n
ti
v
e
 t
re
a
tm
e
n
t 
 
 
Standard 
 
5.60±0.345*** 
 
2.21±0.115** 
 
2.60±0.233*** 
 
Group 
IV 
 
200mg/k 
g 
 
 
8.93±0.720 
 
 
1.45±0.114 
 
 
4.21±0.245** 
 
Group 
V 
 
400mg/k 
g 
 
 
5.98±0.475*** 
 
 
2.16±0.659** 
 
 
2.88±0.227*** 
 
Group 
VI 
 
C
u
r
a
ti
v
e
 t
re
a
tm
e
n
t 
 
 
Standard 
 
 
5.83±0.517*** 
 
 
2.19±0.303** 
 
 
2.87±0.287*** 
 
Group 
VII 
 
200mg/k 
g 
 
 
8.10±0.614 
 
 
1.51±0.367 
 
 
4.39±0.323** 
 
Group 
VIII 
 
400mg/k 
g 
 
 
6.81±0.821** 
 
 
2.10±0.057** 
 
 
3.15±0.173*** 
 
 
All the values are expressed as Mean ± SEM (n=6) 
 
P values *** for P<0.001; ** for P<0.01; * for P<0.05 
 
Values of Group II were compared with Group I and those of Group III to V 
with Group II.
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Graph 3:Effect of methanolic extract of Helicanthes elastica on serum blood 
urea nitrogen 
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Graph 5:Effect of methanolic extract of Helicanthes elastica on serum uric acid.
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Graph 6:Effect of methanolic extract of Helicanthes elastica on urine calcium. 
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Graph 8:Effect of methanolic extract of Helicanthes elastica on total protein in 
urine. 
 
HISTOPATHOLOGICAL ANALYSIS 
 
 
Rat kidney histopathology suggested the following observations in the different 
groups
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Figure 10a) Normal Control                             Figure 10b) Toxic Control 
 
 
 
 
Figure 10c)  Preventive Standard                    Figure 10d) Curative Standard 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10e)  Preventive MHE 200 mg/kg               Figure 10f)  Preventive 
 
MHE 400 mg/kg
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Figure 10g)  Curative MHE 200 mg/kg      Figure 10h) Curative MHE 
400 mg/kg 
 
 
 
 
 
Figure 10a) Normal kidney: Section shows normal glomeruli and Bowman‟s 
 
capsule. Renal tubules are normal .Interstitial tissues appears normal. 
 
 
Figure 10b) Toxic control: Section of kidney shows glomeruli of varying size. 
Bowman‟s capsule widened. Renal tubules appears dilated. There are many 
collections  of  plasma  cells  and  lymphocytes  in  interstitial  tissue.  Foci  of 
calcium oxalate are also seen. 
 
Figure   10c)   Preventive   standard:   Section   shows   normal   glomeruli   and 
Bowman‟s  capsule.  Afferent  and  efferent  arterioles  appear  normal.  Renal 
tubules appear slightly dilated and few inflammatory cells in the interstitial 
tissues. 
 
Figure   10d)   Curative   standard:   Section   shows   normal   glomerulus   and 
Bowman‟s capsule.  Afferent  and  efferent  arterioles  appears  normal.  Renal 
tubules appears normal. A few collections of lymphocytes are seen in interstitial 
tissues. 
 
Figure 10e) Preventive MHE 200mg/kg: Section shows normal glomerulus and 
widened Bowman‟s capsule. Renal tubules appears dilated. Scattered 
inflammatory cells  and plasma cells are present in interstitial tissues.
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Figure 10f) Preventive MHE 400mg/kg: Section shows normal glomeruli and 
Bowman‟s  capsule.  Renal  tubules  appears  normal.  Interstitial  tissues  also 
appears normal. 
 
Figure 10g) Curative MHE 200mg/kg:  Section shows decreased cellularity of 
glomerulus.  Bowman‟s capsule  appears  slightly  dilated.  There  are  foci  of 
calcification. Interstitial tissues showed increased amount of lymphocytes and 
plasma cells. 
 
Figure 10h) Curative MHE 400mg/kg: Section shows normal glomeruli and 
Bowman‟s capsule.  Afferent  and  efferent  arterioles  appears  normal.  Renal 
tubules appears normal. Very few collections of lymphocytes in the interstitial 
tissue. 
 
J.NEPHROPROTECTIVE ACTIVITY 
 
 
J.1.Effect on percentage change in body weight 
 
.The initial  and  final  body weights  of animals  of control  and  experimental 
groups were taken and percentage change in body weight was calculated and is 
shown in table  8. Weight of the animals was significantly reduced in cisplatin 
treated animals (Group II) when compared with normal control (Group I). 
Decrease in body weight showed significant improvement in the body weight.
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Table 8 : Effect of MHEon % change in body weight 
 
 
 
Groups 
 
Treatment 
 
% Change in body weight 
 
Group I 
 
Normal Control 
 
-2.18±0.3791 
 
Group II 
 
Toxic control 
 
18.71±2.9696*** 
 
Group III 
 
Standard drug 
 
-3.45±0.6511*** 
 
Group IV 
 
MHE 200 
 
-8.21±2.0000** 
 
Group V 
 
MHE 400 
 
-4.00±0.6168*** 
 
All the values are expressed as Mean ± SEM (n=6) 
 
P values *** forP<0.001; ** for P<0.01; * for P<0.05 
 
Values of Group II were compared with Group I and those of Group III to V 
with Group II. 
 
 
 
J.2.Effect on Serum Urea 
 
Serum urea level of the control and experimental rats on last day of experiment 
are shown in Table 9. The serum urea level of the normal control rats (Group I) 
was  29.86±  1.0607  mg/dl,  while  it  was  significantly  elevated  to  59.25± 
3.3767mg/dl in animals treated with cisplatin (Group  II).  In Group  III, the 
animals which received Cystone, the standard drug significantly reduced the 
serum urea to 35.87 ±3.6114mg/dl. The animals which received plant extract at 
doses 200 and 400 mg/kg body weight (Group IV and Group V) significantly 
reduced the serum urea to 49.07 ± 2.6755 and 40.04±4.2038mg/dl respectively. 
The statistical result showed, group IV and Group V (MHE 200mg/kg and
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400mgkg  respectively)  reduced  the  serum  urea  levels  at  a  significance  of 
 
 
 
P<0.01 and P<0.05 respectively. 
 
J.3.Effect on serum creatinine 
 
Serum  creatinine  level  of  the  control  and  experimental  rats  on  last  day of 
experiment are shown in Table 9. The serum creatinine level of the normal 
control  rats  (Group  I)  was  0.60  ±0.1032  mg/dl,  while  it  was  significantly 
elevated to 3.10 ± .4024 mg/dl in animals treated with cisplatin (Group II). In 
Group III, the animals which received Cystone,the standard drug significantly 
reduced the serum creatinine to 1.033 ± 0.3283.  The animals which received 
plant extract at doses 200 and 400 mg/kg body weight (Group IV and Group V) 
significantly reduced the serum creatinine to 2.130 ± 0.2231 and 1.53 ± 0.1115 
mg/dl respectively. The statistical result showed, group IV and Group V (MHE 
200mg/kg and 400mg/kg respectively) reduced the serum creatinine levels at a 
significance of P<0.01. 
J.4.Effect on levels of Serum Total proteins 
 
Serum total protein level of the control and experimental rats on last day of 
experiment are shown in Table 9.The serum total protein level of the normal 
control rats (Group I) was 3.09 ±0.2393g/dl, while it was significantly elevated 
to 5.60 ± 0.1719g/dl in animals treated with cisplatin (Group II). In Group III, 
the animals which received Cystone,the standard drug significantly reduced the 
serum total protein levelto 3.45 ± 0.32886g/dl. The animals which received 
plant extract at doses 200 and 400 mg/kg body weight (Group IV and Group V) 
significantly reduced  the  serum  total  protein  to  4.41  ±  0.3818  and  3.93  ± 
0.2331g/dl   respectively.   The   statistical   result   showed,   Group   V   (MHE 
 
400mg/kg) reduced the serum total protein levels at a significance of P<0.01.
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J.5.Effect on levels of Serum uric acid 
 
Serum uric acid level of the control and experimental rats on last day of 
experiment  are  shown  in  Table  9.The  serum  uric  acid  level  of  the  normal 
control rats (Group I) was 1.8788 ± 0.1603mg/dl, while it was significantly 
elevated to 4.03 ±  0.2871mg/dl in animals treated with cisplatin (Group II). In 
Group III, the animals which received Cystone,the standard drug significantly 
reduced the serum uric acid levelto 2.39 ± 0.3232mg/dl. The animals which 
received plant extract at doses 200 and 400 mg/kg body weight (Group IV and 
Group V) significantly reduced the serum uric acid level to 3.15 ± 0.2424 and 
2.4545  ±  0.3718mg/dl  respectively.  The  statistical  result  showed,  Group  V 
(MHE  400mg/kg)  reduced  the  serum  uric  acid  levels  at  a  significance  of 
P<0.01.
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Table 9 . Effect of methanolic extract of Helicanthes elastica on Serum urea, 
Serum creatinine, Serum Total protein and Serum Uric acid in cisplatin induced 
renal toxicity 
 
 
Group 
s 
 
Treatme 
nt 
 
Serum urea 
mg/dl 
Serum 
creatinine 
mg/dl 
 
Total protein 
gm/dl 
 
Uric acid 
mg/dl 
 
Group 
I 
 
Normal 
control 
 
29.86±1.060 
 
0.60±0.103 
 
3.09±0.239 
 
1.87±0.160 
 
Group 
II 
 
Toxic 
control 
 
 
59.25±3.376*** 
 
3.10±0.402*** 
 
5.60±0.171*** 
 
4.03±0.287*** 
 
Group 
III 
 
 
Standard 
 
 
35.87±3.611*** 
 
1.03±0.328*** 
 
3.45±0.328*** 
 
2.39±0.323** 
 
Group 
IV 
 
MHE 
200 
 
 
49.07±2.675* 
 
2.13±0.223** 
 
4.41±0.381 
 
3.15±0.242 
 
Group 
V 
 
MHE 
400 
 
 
40.04±4.203** 
 
1.53±0.111** 
 
3.93±0.233** 
 
2.45±0.371** 
All the values are expressed as Mean ± SEM (n=6) 
 
P values *** forP<0.001; ** for P<0.01; * for P<0.05 
 
Values of Group II were compared with Group I and those of Group III to V 
with Group II.
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Graph 9 . Effect of methanolic extract of Helicanthes elastica on serum urea in 
cisplatin induced renal toxicity 
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Graph  10:  Effect  of  methanolic  extract  of  Helicanthes  elastica  on  serum 
creatinine in cisplatin induced renal toxicity
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Graph 11. Effect of methanolic extract of Helicanthes elastica on serum total 
protein in cisplatin induced renal toxicity. 
 
 
 
5 
 
4.5 
 
4 
 
3.5 
 
3 
 
2.5 
 
2 
 
1.5 
 
1 
 
0.5 
 
0 
 
 
 
*** 
 
 
 
 
 
 
 
 
 
**                                 
** 
 
 
 
 
 
 
 
 
 
 
 
Serum Uric Acid
Normal 
control 
Toxic 
Control 
Standard 
Group 
MHE 200    MHE 400
 
 
Graph 12:Effect of methanolic extract of Helicanthes elastica on serum uric 
acid in cisplatin induced renal toxicity
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HISTOPATHOLOGICAL ANALYSIS 
 
Rat kidney histopathology suggested the following observations in different 
groups 
 
 
 
 
 
 
Figure11a) Normal Kidney                        Figure11b) Toxic Kidney 
(Cisplatin treated) 
 
 
 
Figure11c) Cisplatin + Standard drug        Figure11d) Cisplatin + MHE 
200mg /kg
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Figure11e) Cisplatin +MHE400mg/kg 
 
Figure 11a) Normal control: Section of kidney shows normal structure. 
Glomeruli  show  normal  cellularity  and  vasculature  is  normal.  Bowman‟s 
capsule appears normal. Renal tubules do not show any specific changes. There 
are no inflammatory cells or any other abnormal findings. 
 
Figure11b) Toxic control: Section shows smaller glomeruli. Bowman‟s capsule 
is widened. Glomeruli show diminished cellularity. Interstitial tissues show 
collection of lymphocytes and plasma cells. Many tubules appear dilated with 
flattened lining cells. 
 
Figure11c) Cisplatin + Standard drug Cystone: Section shows kidneys with 
normal glomeruli. Bowman‟s capsule is normal. Afferent and efferent arterioles 
are normal. There are few collections of lymphocytes. Renal tubules are normal. 
 
Figure 11d) Cisplatin + MHE 200g/kg: Section of kidney shows glomeruli of 
varying size, some of the glomeruli are normocellular and many glomeruli show 
decreased cellularity. Bowman‟s capsule is widened. There are small areas of 
necrosis with collections of lymphocytes and plasma cells, some of the tubules 
are dilated and lined by flattened cells. 
 
Figure 11e) Cisplatin + MHE 400mg/kg: Section of kidney shows normal 
glomeruli and Bowman‟s capsule is slightly widened. Renal tubules appears 
almost normal. Very few collection of lymphocytes and plasma cells are present 
in the interstitial tissue. 
Page 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 100 
 
 
 
 
DISCUSSION 
 
 
Antiurolithiatic activity 
 
 
A number of animal models using rats have been used to induce calcium oxalate 
urolithiasis. The most reliable and hence commonly employed method is to 
provide ethylene glycol and ammonium chloride in drinking water to rats. 
Therefore, in the present study the anti urolithiatic activity of methanolic extract 
of  Helicanthes  elastica  is  evaluated  using  the  ethylene  glycol  induced 
urolithiasis in rat models. 
 
The  biochemical  mechanism  of  ethylene  glycol  and  ammonium  chloride 
induced urolithiasis are related to an increase in the urinary concentration of 
oxalate. Ethylene glycol is readily absorbed along the intestine and is 
metabolized in the liver to oxalate leading to hyperoxaluria. Due to the poor 
solubility of oxalate it precipitates in the urine as calcium oxalate. High oxalate 
levels and calcium oxalate crystals especially in the nephron damage epithelial 
cells leading to heterogeneous nucleation followed by causing aggregation of 
crystals. Furthermore ammonium chloride has been reported to accelerate 
lithiasis. 
 
Male Wistar rats were selected to induce urolithiasis because the urinary system 
of male Wistar rats has more resemblance to that of humans.In addition earlier 
studies have reported that the amount of stone deposition in female rats was 
significantly less compared to male rats  due because of enhancing capacity of 
testosterone and inhibiting capacity of oestrogen in stone formation. 
 
Body weights of toxic group rats markedly reduced at the end of the study 
period due to the decreased feed intake. Body weights of test group rats were 
also reduced but the rats in the standard group tries to manage their weight loss 
at the end of study period. 
 
As reported in the previous antiurolithiatic studies 
48,49
decrease in urine volume 
was  observed  in  ethylene  glycol  induced  urolithiatic  rats.  The  methanolic 
extract of HE treatment also increased urine output but less than the stone 
induced group. The urine output of the test group was high when compared with  
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the  normal  group.  This  may be  due  to  the  diuretic  activity of  Helicanthes 
elastica. 
 
Consistent with previous reports, 
46,47
increased lipid peroxidation has been 
reported in the kidneys of the rats treated with ethylene glycol. The elevated 
oxalate concentration has been reported to induce lipid peroxidation and cause 
renal damage by reacting with the poly unsaturated fatty acids in the cell 
membrane. This renal damage was indicated by the elevated levels of creatinine, 
uric acid and BUN in the serum which are the markers of glomerular and 
tubular damage. The MHE treatment showed to prevent the elevation of serum 
levels of these markers. This indicates that MHE acts by inhibiting the lipid 
peroxidation and thereby reduces the extent of tubular dysfunction. The MHE 
has shown significant restoration indicating better control on the progress of 
pathology which can be termed as an important characteristic to label it as an 
ideal therapy. 
 
As reported in some previous studies
46,  47  
stone induction by ethylene glycol 
caused an increase in the concentration of calcium, oxalate and total protein and 
a decrease in the concentration of magnesium in the urine. In the present study, 
observed hypercalciuria in ethylene glycol induced urolithic rats favour the 
nucleation  and  precipitation  of  calcium  oxalate  which  leads  to  subsequent 
crystal   growth.   Hyperoxaluria  is   a  more  significant   risk   factor   in   the 
pathogenesis of renal stone than hypercalciuria. The total protein level was also 
increased in the lithiatic group. The treatment with MHE significantly reduced 
the levels of oxalate, calcium and total protein in urine. The potency of the 
extract may be due to its ability to inhibit some steps of oxalate synthesis or due 
to  the  ability to  decrease  the  calcium  formation.  The  treatment  with  MHE 
showed to decrease the rate of oxalate, calcium and total protein and thereby 
reduced the risk of stone formation. 
 
Magnesium is one of the urinary inhibitors of crystallization .Low levels of 
magnesium are encountered in stone-forming rats as well as in patients with 
renal stones. Magnesium is reported to form a complex with oxalate and reduce 
the supersaturation of calcium oxalate by reducing the saturation of calcium 
oxalate and as a consequence it reduced the growth and nucleation rate of
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calcium  oxalate  crystals. 
125,126  
In  the  present  study,  the  MHE  restored  the 
magnesium excretion near to the normal and thus reduced the growth of calcium 
oxalate crystals. Therefore, the crystallization inhibitory potential of MHE could 
be a result of increased magnesium content of the urine of MHE treatment rats. 
 
Histopathological  studies  shows  that  kidney sections  of the  calculi  induced 
animals showed accumulation of calcium oxalate deposit which causes marked 
histological changes such as dilation of the proximal tubules along with the 
interstitial inflammation. The MHE treatment decreased the calcium oxalate 
deposits and also reduced the damages to the renal tubules. This may be in part 
due to the antioxidant effect of the plant extract. 
 
Cystone, a marketed antiurolithiatic composite herbal preparation, is reported to 
have a protective effect on calcium oxalate urolithiasis. It prevents the 
accumulation, deposition and supersaturation of the stone forming constituents 
and thereby inhibits the formation of kidney stones. Cystone also dissolves 
kidney stones by causing the dissolution of mucin which is responsible to bind 
the stone particles together. Furthermore it has a diuretic action that flushes out 
comparatively smaller stones from kidneys
36,126,128  
.In the present study, both 
 
preventive as well as curative regimens of MHE were effective in reducing the 
risk of stone formation, decrease in renal tissue injury, reducing the crystal size 
and thus facilitating easy expulsion and restoring normal kidney architecture. 
However the preventive effect of MHE was more effective than its curative 
treatment .This may be due to more potent and anti aggregatory effect of MHE 
on stone forming constituents than its effect on dissolution of  preformed stones 
suggesting preferable use of MHE in prevention of kidney stones especially in 
cases of recurrence. 
 
Nephroprotective Activity 
 
 
Nephrotoxicity is an undesired side effect of chemotherapy in general. Most 
chemotherapy drugs targets pathways that are essential to dividing cells. Several 
studies have now documented the importance of reactive oxygen metabolites 
(ROM) in cisplatin and gentamicin induced renal damage. Nephrotoxicity of the 
drugs is usually associated with theiraccumulation in renal cortex, dependent 
upon their affinityto kidneys and on kinetics of drug trapping process. A 
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minimum dose of cisplatin (5 mg/kg body weight) wassufficient to induce 
nephrotoxicity in rats. Cisplatin isknown to accumulate in mitochondria of renal 
epithelialcells and induces ROS primarily by decreasing the activityof 
antioxidant enzymes and by depleting intracellular concentrations of GSH and 
also causes the peroxidation ofmembrane lipids. Cisplatin covalently binds to 
DNAbases and disrupts DNA functions. The cytotoxic action ofthe drug is often 
thought to be associated with its abilityto bind DNA to form cisplatin-DNA 
adducts. Cisplatininduced oxidative stress can activate some protein 
kinases(MAPKs) c-Jun N-terminal kinase (JNK) and p38 whichsensitize the 
injured cell to apoptosis. 
 
Wistar rats of either sex were chosen for the study. Body weights of toxic group 
rats markedly reduced at the end of the study period due to the decreased feed 
intake. Body weights of the test group rats were also reduced but the rats in the 
standard group tries to manage their weight at the end of the study period. 
 
As reported in various studies 
97,129
Cisplatin exposure results in varying degree 
of lipid peroxidation, inhibition in the activities of antioxidant enzymes and 
alterations of biochemical parameters and genomic DNA damage in kidneys of 
rats. It was reported that cisplatin-induced renal toxicity was evidenced by the 
elevated biochemical markers such as serum urea, serum creatinine, Uric acid 
and total protein. 
 
Creatinine is a spontaneously generated cyclic derivative of creatine. Creatinine 
is chiefly filtered out of the blood by the kidneys through glomerular filtration 
and proximal tubular secretion. There is little-to-no tubular reabsorption of 
creatinine. If the filtering of the kidney is deficient, creatinine blood levels 
increase. This suggests diminished ability of the kidneys to filter these waste 
products from the blood.
130 
Uric acid normally dissolves in the blood, processes 
 
through the kidney, and leaves the body in the urine. If the body makes extra 
uric acid, or if the kidneys cannot clear enough of it, then uric acid levels in the 
blood  will  become  too  high,  a  condition  known  as hyperuricemia.  In  the 
present  investigation,  serum  creatinine  level  was  significantly  decreased  by 
MHE at both doses showed its nephroprotective action on cisplatin-induced 
nephrotoxicity.
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Urea is a by-product of metabolism of protein. This waste product is generated 
in  the liver, then filtered  from  the blood  and  excreted in  the urine by the 
kidneys. The Urea  test measures the  amount of urea in the blood sample. High 
urea   levels   indicate   kidney   dysfunction.   It   was   reported   that   serum 
concentration of creatinine, urea, uric acid and total proteins depends largely on 
the glomerular infiltration
131,132
 
 
 
In  the  present  study,  serum  urea,  BUN,  and  total  protein  level  were 
significantly decreased  by MHE  at  both  doses  showed  its  nephroprotective 
action  on  cisplatin-induced  nephrotoxicity.  SOD is  the first line of defense 
against free radical induced oxidative stress. It is responsible for catalytic 
dismutation of highly reactive and potentially toxic superoxide radical to 
hydrogen peroxide. Cisplatin caused a significant decrease in SOD activity. The 
present investigation showed SOD activity increased by the administration of 
MHE (400 mg/kg) implicates its antioxidant and nephroprotective activity. GSH 
is an intracellular reductant and plays a pivotal role in catalysis, metabolism, 
and transport. It protects cells against peroxides, free radicals, and other toxic 
compounds . Reduced GSH neutralizes the hydroxyl radical and plays an 
important role against oxidative stress and inflammatory responses. The 
nephrotoxicity induced  by  cisplatin  in  rats  is  due  to  decrease  of  GSH  -S- 
transferase-γ activity . Cisplatin decreases the GSH content in kidney, indicating 
oxidative stress. Cisplatin inhibits the activity of antioxidant enzymes (GSH and 
LPO)  in  rat  kidneys  suggests  that  cisplatin  nephrotoxicity  results  from 
generation of reactive oxygen species (Aslam et al.,2013;Sakr et al.,2012;Huang 
et a.,2011). The present study showed GSH content increased by the 
administration of MHE (400 mg/kg) implicates its antioxidant and 
nephroprotective activity. 
 
Cystone a polyherbal formulation inhibit the lipid peroxidation by cisplatin in 
renal corticles at a dose between 500 and 1000mg/kg. Cystone treated animals 
regained the normal blood urea nitrogen, creatinine and uric acid levels. The 
main    mechanism behind the protective effect against cisplatin is through its 
lipid peroxidation inhibition. 
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The histopathology reports also showed that the kidneys of the animals treated 
with the MHE regained the normal structure. The kidneys of cisplatin treated 
animals showed large collection of lymphocytes and plasma cells in interstitial 
tissues. The Bowman‟s capsules were widened and dilated renal tubules. The 
Cystone standard drug treated animals also regained normal structure. 
 
Phytochemical   screening   of   MHE   showed   the   presence   of   glycosides, 
flavanoids, triterpene, steroids, tannin, and phenolic compounds. Anti-oxidant 
activity of MHE has been already reported. Flavanoids are well known potent 
antioxidant  and  free  radical  scavengers.  The  whole  plant  of  MHE  arerich 
sources of flavonoids which have been shown to possess several biological 
properties related to antioxidant mechanism. In the present investigation, the 
nephroprotective effect showed by MHE may be due to the presence of 
flavonoids and related compounds. 
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CONCLUSION 
 
 
 The present study was designed to evaluate the antiurolithiatic and 
nephroprotective activity of methanolic extract of Helicanthes elastica. 
 Phytochemical analysis of the extract reported positive result for 
carbohydrates, flavonoids, phenolics, glycosides, tannins, steroids and 
triterpenoids. 
  In the antiurolithiatic study, ethylene glycol was given orally to induce 
urolithiasis in two different doses for preventive and curative treatment 
regimen. 
  The effect of the plant extract was assessed in terms of serum markers 
like blood urea nitrogen, uric acid and creatinine and urine markers like 
calcium, magnesium and total protein. Histopathological studies were 
also done to support the results. 
  Extract treated groups of animals showed significant improvement in 
serum and urine markers and the kidney damage due to urolithiasis 
produced by ethylene glycol. 
  Based  on  the  results  obtained,  it  can  be  concluded  that  methanolic 
extract of Helicanthes elastica possess antiurolithiatic activity against 
ethylene glycol induced urolithiasis. 
  In  the nephroprotective study,  Cisplatin was  given to induce kidney 
toxicity. 
  Extract was orally administered to experimental animals in two different 
doses. 
  The effect of    the extract was assessed in terms of serum markers like 
urea, creatinine, uric acid and total protein. Histopathological studies 
were also done to support the results. 
  Extract treated groups of animals showed significant improvement in 
serum markers and the kidney damage caused by cisplatin. 
  Based  on  the  results  obtained,  it  can  be  concluded  that  methanolic 
extract of Helicanthes elastica possess nephroprotective activity against 
cisplatin induced nephrotoxicity. 
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